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ABSTRACT 
  
Objectives: There has been considerable discussion about creating a third class of drugs 
which would not require a prescription, but require a pharmacist’s consultation upon purchase. 
Very recently the Food and Drug Administration (FDA) held a hearing which repositioned a 
third class as an expanded nonprescription drug class termed as the “new paradigm” using 
certain innovative technologies. The specific objectives of this study were to: 1) Measure 
community pharmacists’ attitudes toward an expanded nonprescription drug class under the 
FDA’s proposed “new paradigm”; 2) determine if attitudes of community pharmacists toward 
an expanded nonprescription drug class under the FDA’s proposed “new paradigm” differ by 
type of practice setting, location of community pharmacy, region in which the practice is 
located, degrees earned, years actively practicing pharmacy, position in the pharmacy, perceived 
workload, and pharmacy association affiliation; and 3) determine which drugs community 
pharmacists believe would be acceptable additions to an expanded definition of nonprescription 
drugs under the FDA’s proposed “new paradigm”. 
Methods: This cross-sectional study was conducted using a self-report, web-based 
survey. 462 completed responses from a national convenience sample of community pharmacists 
were obtained. The survey items were either obtained from the existing scales in the literature or 
developed based on the FDA’s proposed guidelines for the new paradigm. A principal 
components analysis (PCA) with VARIMAX rotation and reliability analyses were conducted to 
determine the factors affecting community pharmacists’ attitudes toward the new paradigm. 
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Multivariate Analysis of Variance (MANOVA) was used to determine whether attitudes toward 
the new paradigm differed based on aforementioned respondent characteristics.  
Results and Conclusions: Respondents were generally positive about the provision of 
patient care under the proposed new paradigm. The results from the PCA suggested that 
community pharmacists’ attitudes toward the new paradigm is comprised of six factors including 
patient care, workflow, patient safety, non-pharmacist providers, pharmacist burden and access. 
Respondent attitudes differed based on certain practice and demographic variables. Not 
surprisingly, the majority of respondents indicated that Plavix® and Ambien® should still be 
dispensed as prescription drugs even upon implementation of the “new paradigm” while 
Lipitor®, Glucophage®, Viagra® could be switched to the “new paradigm”. 
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INTRODUCTION 
Access to prescription medications continues to be a significant public health concern 
(Food and Drug Administration, 2012a) and is thought to lead to undertreatment of disease and 
other effects on the healthcare system (Karst, 2012).  Limited access to prescription medications 
can be attributed to several factors, such as cost, perceived need, and access to a community 
pharmacy (Ried et al., 2011).  Additionally, limited access to prescription medications can also 
be attributed to cost or time required to visit a physician for a prescription or prescription refill 
(Food and Drug Administration, 2012a).  Making prescription drugs accessible as over-the-
counter (OTC) medications, particularly through prescription-to-OTC switches, may resolve 
some of these access issues.  However, for some drugs, the risk associated with use or potential 
for abuse or misuse of the drug may make it impractical to switch a drug from prescription 
status to OTC status (Food and Drug Administration, 2012b). 
It is for these reasons that the debate about creating a third class of drugs, also referred to 
as a “behind-the-counter”, “BTC”, “pharmacist only”, or “pharmacist controlled” class of drugs 
has been sparked and reignited by various stakeholders (Karst, 2012).  Such a class of 
medications would include those drugs that do not require a prescription, but require a 
pharmacist’s consultation upon purchase (Sood et al., 2008).  This class is purported to provide 
patients with better access to certain drugs while still being monitored by a pharmacist (Cranor, 
2003).  In addition to improving access to certain drugs, a third class of drugs may alleviate 
safety concerns about drugs that might otherwise be available OTC.  Pharmacist monitoring 
under the third class would minimize the risk of patients misdiagnosing their condition and 
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reduce the potential for abuse or misuse that make certain drugs unsafe to market as over-the-
counter (OTC) products (Oster et al., 1990). 
While these deliberations have never brought such a class to fruition, some medications 
have been classified as BTC drugs on a case-by-case basis.  Pseudoephedrine was re-classified 
from an OTC to BTC class as a result of the Combat Methamphetamine Act because of a 
documented history of abuse as an OTC drug (Drug Enforcement Administration, 2005). 
Levonorgestrel (Plan B) was formerly a prescription-only product and is now dual-labeled to be 
dispensed as a OTC drug to patients 17 years of age and older and as a prescription to patients 
younger than 17 years of age (Food and Drug Administration, 2006). Recently, Plan B was 
switched to OTC status for females 15 years of age or older. However, the Obama 
administration has appealed this decision of the FDA and thus the matter is under further review 
(American Pharmacists Association, 2013). 
Very recently, the third class debate was sparked again with a February 28, 2012 Federal 
Register notice announcing a late March public hearing for the FDA to gather input about how 
to address the issue of such a class of drugs (Karst, 2012).  Unlike previous public hearings 
about expanding a BTC class of drugs, the 2012 public hearing entitled “Using Innovative 
Technologies and Other Conditions of Safe Use to Expand Which Drug Products Can Be 
Considered Nonprescription” repositions a third class of drugs not as a BTC class, “but rather as 
a ‘new paradigm’ under which FDA “would approve certain drugs that would otherwise require 
a prescription for nonprescription use . . . under conditions of safe use”(Karst, 2012).  These 
“conditions of safe use,” says the FDA, “would be specific to the drug product and might 
require sale in certain pre-defined health care settings, such as a pharmacy” (Karst, 2012). 
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Therefore, the FDA is exploring the expansion of the current definition of nonprescription drugs 
as currently defined by the Durham Humphrey Amendment (Fink et al., 2006).  
In concept, the idea of expanding the current definition of nonprescription drugs does not 
appear to markedly differ from previous proposals outlining a third class of drugs.  However, 
several aspects of the new paradigm such as establishing conditions of safe use and using 
innovative technologies as one of the potential ways to dispense of these types of drugs does 
appear novel.  The “new paradigm” will be discussed in detail in the forthcoming literature 
review. 
Study Significance 
Following the March 2012 public hearing on the new paradigm, the FDA seeks to elicit 
comments, opinions and suggestions about the proposed new paradigm from the key 
stakeholders in the field of healthcare.  Arguably, the community pharmacist is one of the most 
significant stakeholders in expanding the definition of nonprescription drugs.  In response to the 
FDAs need for feedback on the “new paradigm”, this study measures community pharmacists’ 
attitudes toward the expansion of the definition of nonprescription drugs in the United States. 
Study Objectives 
The specific objectives of this study are to: 
1) Measure community pharmacists’ attitudes toward an expanded nonprescription drug 
class under the FDA’s proposed “new paradigm”. 
 
2) Determine if attitudes of community pharmacists toward an expanded nonprescription 
drug class under the FDA’s proposed “new paradigm” differ by type of practice setting, 
location of community pharmacy, region in which the practice is located, degrees earned, 
years actively practicing pharmacy, position in the pharmacy, perceived workload, and 
pharmacy association affiliation. 
 
3) Determine which drugs community pharmacists believe would be acceptable additions 
to an expanded definition of nonprescription drugs under the FDA’s proposed “new 
paradigm”. 
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LITERATURE REVIEW 
History of the Third Class Debate 
The idea of a third class of drugs has been debated ever since the passage of the Durham-
Humphrey Amendment to the Food, Drug and Cosmetic Act in 1951 (Fink et al., 2006).  The 
Durham Humphrey Amendment created two classes of drugs (prescription and non-prescription) 
in the United States (Fink et al., 2006).  In 1964, due to concerns over safety of non-prescription 
sale of drugs such as albuterol, epinephrine and ibuprofen, the American Pharmaceutical 
Association (now the American Pharmacists Association) (APhA) House of Delegates 
recommended the creation of a third class of medications which would not require a 
prescription.  However the clinical necessity and appropriateness of the drug would be 
determined by the pharmacist (Martin, 1991).  Following this, in 1967, the APhA House of 
Delegates suggested that the sale of all codeine-containing cough and cold products and anti-
diarrheal medications should be controlled by pharmacists.  Support from the APhA and the 
National Community Pharmacists Association (NCPA), for an intermediate “transition” class of 
drugs which would be dispensed without a prescription by pharmacists, grew stronger after the 
first Rx-to-OTC switch was made in 1975 (Marshall, 1992).  Several state pharmacy 
associations (such as the California and Florida Pharmacy Associations) have sponsored 
legislative resolutions that gave prescribing authority to pharmacists for drugs that are potential 
candidates for a prescription to non-prescription switch.  In doing so, these states successfully 
created a “transition” category of drugs (Marshall, 1992). 
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Although some BTC drugs currently exist in the United States, the FDA has always 
vetoed the expansion of a third class of drugs on the grounds that it is not “necessary” (Sega & 
Sullivan, 2011).  In 1995 the Government Accountability Office (GAO) issued a report 
evaluating the need for a BTC class of drugs. The GAO report analyzed similar systems in ten 
other countries such as the United Kingdom, Canada, and Australia.  The report’s main focus 
was on the effect of a third class of drugs on drug use/misuse, access and cost to patients.  The 
GAO concluded that there was not enough evidence to add another class of drugs to the United 
States healthcare system (Marshall, 1992).  In 2007, this topic reemerged in a FDA public 
hearing.  The GAO was asked to revise its 1995 report.  However, the GAO, after reviewing 86 
drugs from 5 countries, concluded that the need for a third class of drugs in the United States was 
“still unclear” (Government Accountability Office, 2009) and that the FDA would need more 
evidence from key stakeholders before such a drug class could be operationalized and expanded. 
The third class debate was reignited again in 2011 when Research Director of the Center for 
Drug Evaluation and Research, Dr. Janet Woodcock, sought to revive the discussion at the Food 
and Drug Law Institutes annual conference (Karst, 2012).  
Very recently, the third class debate was sparked again with a February 28, 2012 Federal 
Register notice announcing a late March public hearing for the FDA to gather input about how 
to address the issue of such a class of drugs (Karst, 2012).  Unlike previous public hearings 
about expanding a BTC class of drugs, the March 2012 public hearing entitled “Using 
Innovative Technologies and Other Conditions of Safe Use to Expand Which Drug Products 
Can Be Considered Nonprescription” repositions a third class of drugs not as a BTC class, “but 
rather as a ‘new paradigm’ under which FDA “would approve certain drugs that would 
otherwise require a prescription for nonprescription use . . . under conditions of safe use” (Karst, 
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2012). These “conditions of safe use,” says the FDA, “would be specific to the drug product and 
might require sale in certain pre-defined health care settings, such as a pharmacy” (Karst, 2012).  
Thus, the FDA is exploring the expansion of the current definition of nonprescription drugs as 
currently defined by the Durham Humphrey Amendment (Fink et al., 2006).  
To ensure the safe and appropriate use of these nonprescription drugs, the FDA would have 
to establish the conditions for safe use for all such drugs on a case-by-case basis. For example, 
the patient might be required to talk to a pharmacist, or need to have a diagnostic test performed 
or visit a physician for the first prescription of the drug, but the subsequent refills could be 
obtained without a prescription.  The FDA is also considering awarding dual status (i.e., both 
prescription and nonprescription) to certain drugs after determining the conditions for their safe 
use (Karst, 2012). 
The FDA stated that in order for such a system of patient-directed self-care to work 
efficiently, various technologies such as kiosks at pharmacies, computer algorithms or 
questionnaires on the Internet, which would help the patient to self-diagnose correctly, could be 
used.  Such technologies would be able to suggest appropriate medications to the patient for the 
particular condition.  Additionally, the patient would be informed about the conditions for the 
safe use of the specific drug and the foods/drugs with which that drug might be contraindicated. 
Alternatively pharmacists would recommend the appropriate drug based on the patient’s medical 
records and inform the patient about the conditions for the safe use of the drug (Food and Drug 
Administration, 2012c). 
Benefits and Limitations of an Expanded Definition of Nonprescription Drugs  
There are several potential benefits to establishing an expanded definition of 
nonprescription drugs.  Doing so would ensure better access to certain medications especially in 
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rural areas and at odd times (i.e. weekends, holidays, late evenings) when procuring a 
prescription might be difficult (Ried et al., 2011).  Accessing an expanded nonprescription drug 
without a prescription could arguably save a patient both the time and money involved with a 
physician visit (Ried et al., 2011).  Patient medication monitoring by the pharmacist through 
Medication Therapy Management (MTM) has shown to improve adherence and health outcomes 
(Bunting, Smith, & Sutherland, 2008) and thus there is a potential to see similar outcomes under 
the new paradigm.  An expanded nonprescription drug class could arguably extend the 
pharmacist’s role in healthcare; therefore further enhancing the value of the pharmacy profession 
by elevating pharmacists’ involvement in patient treatment decision-making (Ried et al., 2011).  
Such a drug class can also impact strategies, which pharmaceutical companies adopt, for 
their drugs nearing patent expiration.  The existence of a well-developed expanded 
nonprescription drug class would add to the drug life-cycle extension avenues available to 
pharmaceutical manufacturers because now a drug nearing the end of its patent term could be 
approved for dispensing as part of the expanded nonprescription drug class.  Additionally, after 
the FDA hearing of March 2012, the FDA might consider dual availability of a drug as both 
prescription and nonprescription under the new paradigm (Food and Drug Administration, 
2012c).  Such a move might be beneficial for manufacturers as they would be able to market an 
on-patent prescription drug as nonprescription as well. 
Such a class of drugs has the potential to foster better patient-pharmacist as well as 
physician-pharmacist relationships.  This is predicated on the idea that qualified healthcare 
professionals would work collaboratively with patients to appropriate decisions about the 
patients’ medication regimen (Ried et al., 2011).  However, if physicians are not comfortable 
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with the idea of pharmacists recommending and monitoring patients’ medications, or ordering 
diagnostic tests, then pharmacist-physician relationships could be negatively affected. 
There are certain limitations associated with expanding the definition of a 
nonprescription drug class.  These drugs could have a greater abuse/misuse potential than 
prescription drugs as patients may “shop” (i.e., acquire multiple fills and refills) for these drugs 
from one pharmacy to the other (Ried et al., 2011) unless controlled for by the FDAs “conditions 
for safe use” (Food and Drug Administration, 2012c).  Implementing an expansion of 
nonprescription drugs would require a greater investment of time on the part of the pharmacist 
for patient counseling and documenting patients’ medical records (Ried et al., 2011).  
Reimbursing pharmacists for the additional time spent on providing these services by third party 
payers is another concern (Ried et al., 2011).  An expanded nonprescription definition could also 
result in increased pharmacist liability (Department of Health and Human Services, 2012).  
Finally, infrastructure changes would have to be made in pharmacies to provide 
additional private patient counseling rooms as well space to store these drugs (Ried et al., 2011).  
Another important factor that must be considered is patient cost.  It is anticipated that initially 
expanded nonprescription drugs will increase out of pocket expenses for patients as they may not 
be covered by insurance.  However, overall costs in the long run will depend upon third party 
coverage of drugs as well as mortality and morbidity rates as a result of pharmacists’ 
interventions (Ried et al., 2011).  
Drug Candidates for an Expanded Definition of Nonprescription Drugs 
Organizations such as APhA and the Academy of Managed Care Pharmacy have 
suggested that only those medicines that are used for ailments that involve limited physical 
assessment (i.e., easy self-diagnosis) and whose lab results can be easily interpreted could 
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potentially be dispensed under an expanded definition of nonprescription drugs (Ried et al., 
2011).  Prescription drugs having a good benefit-to-risk ratio could be included in such a drug 
class (Ried et al., 2011).  The pharmacist must be able to order and access lab tests when needed 
and electronic health information records must be kept up to date for such a switch to work. 
These drugs should have a manageable side effect profile and they should not put the patient at 
risk for microbial resistance (Ried et al., 2011).  For certain drugs, the patient may need to 
consult the physician initially, but the pharmacist may be consulted for subsequent refills 
(Department of Health and Human Services, 2012).  
With these considerations in mind, the discussion as to which drugs would make ideal 
candidates for an expanded definition of nonprescription drugs begins.  Prospective candidates 
for this class of drugs include medications for treating hypertension, hyperlipidemia, asthma, 
gastrointestinal reflux, allergies, pain, migraines, and obesity (Ried et al., 2011).  Recently, there 
has been significant attention paid to the inclusion of statins in either a traditional or expanded 
nonprescription class.  Statins have a history of being well tolerated and effective reducing 
cholesterol (Nag, Pearson, Ma, et al., 2005).  However, it has been estimated that over 60% of 
patients do not receive adequate statin treatment (Nag, Pearson, Ma, et al., 2005).  Therefore, 
there have been several attempts to switch statin drugs to a nonprescription class.   
Merck made unsuccessful efforts to switch Mevacor, its blockbuster cholesterol lowering 
drug, to a nonprescription before its patent expired in 2001 (Wechsler, 2000).  There have been 
endeavors to switch cholesterol-lowering pravastatin and lovastatin to a nonprescription category 
(Sood et al., 2012).  However, these efforts have been rendered null by the FDA due to concerns 
such as inappropriate self-selection, side-effects like rhabdoamyolosis, and the necessity to 
screen liver enzymes (Tinetti, 2008).  Perhaps in the “new paradigm” of an expanded 
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nonprescription drug class, statins may find their fit.  The Federal Register of February 2012 
(Department of Health and Human Services, 2012) states that certain chronic medications may 
be sold under an expanded nonprescription class of drugs after the conditions for its safe use are 
determined.  These conditions of safe use could be established after evidence has been 
established through post marketing surveillance, adverse events reports or epidemiological 
studies which could be sponsored by the manufacturer while they would be carried by 
pharmacists (Marshall, 1992). 
Stakeholder Perspectives on an Expanded Definition of Nonprescription Drugs 
Consumer groups. Generally, consumer groups have voiced support for an expanded 
class of nonprescription drugs. The National Consumers League and the Consumers Union have 
advocated the creation of a class that will increase patient access to safe drugs, after consulting a 
pharmacist, for self-diagnosable conditions (Ried et al., 2011).  These groups have held the 
opinion that such a class of drugs would increase the range of self-diagnosable conditions for the 
patient.  This has the potential to save time and money that would have otherwise been spent on 
a physician visit and would go a long way in alleviating patients’ access problems.  
In September 1991, the National Consumers League sponsored a symposium “Transition 
Class of Drugs: Prescription for Change – Global Perspectives” which illustrated the 
effectiveness of such a class of drugs in countries such as United Kingdom, Australia and 
Canada, where such an expanded nonprescription class already exists (Marshall, 1992).  
However, these groups are concerned about the lack of insurance coverage for these drugs as 
well as patient privacy and comfort level in discussing medication issues at length with the 
pharmacist (Branding & Narula, 2011).  Thus, these organizations have suggested a test phase 
for an expanded nonprescription class of drugs before its eventual implementation.  
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On the other hand, the Consumer Healthcare Products Association (CHPA), formerly 
known as the Nonprescription Drug Manufacturer’s Association (NDMA), believes that the 
current two drug class system in the United States is sufficient and provides enough flexibility to 
the consumer (Ried et al., 2011).  Indeed, it has been argued that an expanded nonprescription 
class of drugs would reduce patient empowerment and increase FDA control over patient 
medication choice and access (Ried et al., 2011).  CHPA estimated that creating a third class 
would reduce the number of available non-prescription options from 750,000 to 55,000 
(Government Accountability Office, 1995).  The CHPA also stated that the number of retail 
establishments, which currently sell OTC medications, would decrease by as much as 80% if a 
majority of OTC drugs were moved behind the pharmacy counter.  Because the CHPA lobbies 
for OTC manufacturers, it fears that an expanded nonprescription class would severely curtail the 
sale of OTC drugs, as seen in the case of pseudoephedrine.  They believe that the current two 
class system “works” and pharmacists want such a move to be implemented for their own 
“economic benefits” (Martin, 1991). 
Professional pharmacy organizations.  Most professional pharmacy organizations such as 
the American Pharmacists Association, American Society of Health System Pharmacists, 
National Association of Boards of Pharmacy, and the National Community Pharmacists 
Association advocate for the implementation of an expanded nonprescription class of drugs 
(Ried et al., 2011). 
The justification provided by them in favor of an expanded class of drugs is that such a 
category will be useful in reducing the side effects of certain OTC drugs, especially in high risk 
patients with asthma, diabetes, bleeding disorders, and effective intervention will ensure 
appropriate drug use (Ried et al., 2011).  They also believe that an expanded category of drugs 
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will increase patient access to essential medications, enhance patient safety and improve the 
quality of patient care (Ried et al., 2011).  They note that pharmacists have the clinical training 
required for reliable monitoring and management of chronic and self-diagnosable conditions 
(Ried et al., 2011).  Pharmacists expect such a class of drugs to decrease healthcare costs in the 
long run as well as promote better collaboration among healthcare teams (Martin, 1991). 
However, certain potential barriers cited by pharmacist organizations to the 
implementation of an expanded nonprescription class are unavailability of specialized training in 
patient diagnosis and follow-up, increased liability, an unacceptable legal and insurance 
framework which will reimburse the pharmacist for the time spent in patient diagnosis and 
counseling (Hunt, 2010), and insufficient space for private patient counseling rooms (Sega & 
Sullivan, 2011).  Although it has been argued that the funding for pharmacists’ reimbursement 
could come from various sources such as Medicare Part D (in a manner similar to how 
pharmacists are reimbursed for MTM), state Medicaid and out-of-pocket from the patient (Levy, 
2008), reimbursement mechanism will likely be unclear until the class is actually expanded.  
A recent statement by the president of the APhA, Thomas Menighan, sums up the above 
arguments very well.  Menighan commented, “While many details of this potential drug 
paradigm need to be worked out through future collaborations, none of them are significant 
enough to stop this important initiative from being enacted.  America's pharmacists view this 
proposal as ‘Yes... if,’ rather than ‘No... but.’  We look forward to working with FDA and other 
healthcare providers and stakeholders to answer the ‘if’ questions and make this concept a reality 
for the benefit of patients and the healthcare system” (American Pharmacists Association, 2012).  
The American Society of Health System Pharmacists (American Society of Health System 
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Pharmacists, 2012) and the APhA have supported the creation of this new drug paradigm though 
released statements after the March 2012 hearing. 
Professional physician organizations.  The American Medical Association (AMA) argues 
that the FDA does not have enough evidence to establish an expanded nonprescription class 
without new legislation and that such a class may actually hamper access to medications (i.e. 
OTC drugs) while increasing cost and risk (American Medical Association, 2010).  The AMA 
argues that pharmacists’ clinical training may not be sufficient to diagnose patients (especially in 
chronic cases) correctly and hence an expanded nonprescription class may be inappropriate.  
Physicians also worry that patients may not feel the need to see their doctor for routine check-ups 
or they might delay care in case of acute conditions (Zwillich, 2007).  Other medical professions 
have also expressed concern over an expanded class of nonprescription drug.  Nutritionists have 
noted that “fewer patients would pursue preventative measures like diet and exercise if they can 
easily buy a pill” (Zwillich, 2007). 
Pharmaceutical manufacturer organizations. The Pharmaceutical Research and 
Manufacturers of America (PhRMA), formerly known as Pharmaceutical Manufacturers 
Association (PMA) has not taken a stand on the issue of an expanded nonprescription class 
(Marshall, 1992).  However, it has been largely estimated that the industry would be skeptical 
about the addition of a transition class of drugs (Marshall, 1992).  It is argued that indecisiveness 
in their opinion exists because pharmacy organizations have not fully defined what should 
constitute of such a class of drugs (Marshall, 1992).  
Current Research in Community Pharmacist Attitudes  
There are certain studies in the current literature which have reported on community 
pharmacists’ attitudes and perceptions toward a potential expanded nonprescription drug class in 
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the United States.  Sega and Sullivan (2011), Hunt et al. (2010) and Prince and Pharo (2008) 
measured attitudes of community pharmacists’ toward the establishment of a permanent BTC 
category of drugs, in the states of Ohio, Idaho and Alabama respectively.  These studies 
examined various issues related to a potential expanded nonprescription drug class in the United 
States such as pharmacist knowledge about an expanded nonprescription drug class, pharmacists’ 
readiness for the establishment of such a class in the United States, reimbursement issues, and 
social and legal aspects surrounding the implementation of such a drug class.  These studies also 
considered pharmacist opinions about pharmacy related factors (staffing, structural changes 
which might be essential), and patient related factors (access, time, monetary concerns).  The 
results of these studies suggested that pharmacists agree that there is a need for a BTC drug class 
in the United States.  Pharmacist readiness for the implementation of a third class of drugs 
appeared to be based on the belief that patients would benefit from having increased access and 
time savings.  However, pharmacists also agreed that certain changes would need to be made in 
the pharmacy and that pharmacists would need some amount of training before a BTC drug class 
is established  
A study by Taylor et al. (2000) explored community pharmacists’ readiness to assess the 
OTC selections of their customers in a Canadian province using the Transtheoretical Model of 
Change.  This study assessed the benefits and limitations of establishing a pharmacist-only class 
of drugs and pharmacists’ level of agreement with the legislative status that had been given to 
such a class of drugs. The results of this study showed that community pharmacists differed 
considerably in their degree of readiness to acknowledge the establishment of pharmacist-only 
class of drug products. A majority of the respondents were not ready to accept the responsibility 
of assessing patients’ OTC selections (57.6% of the respondents were in pre-contemplation 
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stage).  Precontemplators were expectedly less supportive of keeping pharmacist-only agents 
behind the counter. 
Madhavan (1993) examined the conditions preferred by United States community 
pharmacists’ for the sale of Rx-to-OTC switch drugs.  He also assessed if these conditions varied 
significantly with regard to demographics and practice characteristics of the pharmacists.  This 
study suggested community pharmacists’ preferred a permanent pharmacist supervised class (i.e. 
BTC drug class) of drugs over a general unsupervised drug class.  Overall, for switch drugs, 
pharmacists preferred conditions of sale that involved pharmacist supervision rather than 
conditions that did not, although some pharmacists were governed by safety concerns and 
economic issues. 
 The current study seeks to make significant contributions to the literature evaluating 
pharmacists’ attitudes toward an expanded nonprescription drug class.  First, this study employs 
a theoretical framework to describe pharmacists’ attitudes toward an expanded nonprescription 
class of drugs.  Second, a national sample is employed to ensure greater generalizability of 
findings and allow for regional comparisons in attitudes.  Most importantly, this study examined 
pharmacists’ attitudes toward an expanded nonprescription class of drugs specifically under the 
FDA’s recently proposed “new paradigm”. 
Theoretical framework 
With respect to this study, it was considered that an expanded nonprescription class under 
the “new paradigm”, if implemented, would be a new innovation in healthcare because currently, 
only a de-facto BTC class of drugs exists in the United States, with certain drugs added to it on a 
case by case basis.  In fact, the FDA’s March 2012 public hearing was entitled “using innovative 
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technologies and other conditions of safe use to expand which products can be considered 
nonprescription.”  
Rogers defines an innovation as “an idea, practice or object that is perceived as new by 
an individual or other unit of adoption” (Rogers, 2003).  Whenever a new innovation or a major 
policy change is introduced into any field (healthcare in this case) it is essential to understand the 
determinants or the factors that facilitate or impede the adoption and implementation of that 
innovation by the key stakeholders.  An understanding of these determinants is essential for the 
successful implementation of the new innovation because there may be several positive or 
negative factors in addition to the attitude and characteristics of the adopting healthcare 
professional as well as the adequacy of financial resources which can affect the optimum 
adoption and implementation of an innovation. 
Therefore, a theoretical framework based on the determinants of innovation within 
healthcare organizations was adapted from Fleuren, Wiefferink and Paulussen (2004) for use in 
this study.  In this framework, the main stages in the process of incorporating an innovation into 
practice and the related categories of determinants have been structured such that the adopter of 
a new innovation can identify the various determinants that can affect the process of 
incorporating an innovation into practice.  The framework can be found in Figure 1 below.  
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Figure 1: Determinants of Innovation Framework. 
 
 
 
 
 
 
 
  
 
 
The various determinants that impact the process of incorporating an innovation into 
practice can be divided into four broad categories: (i) characteristics of the socio-political 
context refers to rules, legislation and patient characteristics; (ii) characteristics of the adopting 
organization refers to issues such as staff-turnover or involvement in decision-making; (iii) 
characteristics of the adopting person refers to the knowledge, skills, and colleague support 
which the user of the innovation might need; (iv) characteristics of the innovation refers to 
matters such as the ease/complexity of the implementation and use of the innovation, and relative 
advantage the innovation offers over current counterparts (Fleuren, Wiefferink, & Paulussen, 
2004).  
Fleuren, Wiefferink & Paulussen (2004) 
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The four innovation determinants described above were adapted as needed to provide 
theoretical framework for identifying the dimensions of community pharmacists’ attitudes 
toward an expanded definition of nonprescription drugs.  Characteristics of the socio-political 
context were used to describe legal and patient factors related to an expanded nonprescription 
class of drugs under the FDA’s proposed new paradigm.  Characteristics of the organization 
were adapted to characteristics of the pharmacy to describe characteristics of pharmacies that 
would be ultimately implement the expanded nonprescription class of drugs under the FDA’s 
proposed new paradigm.  Characteristics of the adopting person (user) were adapted to 
characteristics of the pharmacists who would adopt the expanded nonprescription class of drugs 
under the FDA’s proposed new paradigm.  Characteristics of the innovation were used to 
describe complexity and relative advantage of the expanded nonprescription class of drugs 
under the FDA’s proposed new paradigm over the current two drug class system. 
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METHODS 
Design 
            This study was conducted with a cross-sectional non-experimental descriptive design 
by means of a self-administered web-based survey which was distributed to a national sample 
of community pharmacists.  
Sample  
                                
Sample description.  A national convenience sample of community pharmacists was used 
in this study.  Using a national sample facilitated investigating regional differences that might 
exist in community pharmacists’ attitudes toward an expanded nonprescription drug class in the 
United States while also facilitating the generalizability of results.  Community pharmacists 
provide the sample frame for this study because they are major stakeholders and would be 
essential to the successful establishment of an expanded nonprescription class of drugs.  The 
sample contained community pharmacists from independent pharmacies, traditional chain 
pharmacies, grocery stores and mass merchandisers. 
Sample source.  The sample of community pharmacists was drawn from a national panel 
of community pharmacists obtained from Delta Marketing Dynamics, a data services company.  
Out of the database maintained by the company, a list of 2800 community pharmacists was 
selected and this served as the respondent sample for the study. 
Sample size. Two estimates were used for calculating the sample size for the study.  In 
the first approach, sample size was determined using the formula mentioned below 
Ns = (Np)(p)(1 - p)/((Np – 1)(B/C)2+(p)(1 – p)) 
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Where Ns is the sample size needed for the size of the survey population and Np is the number of 
units in the survey population from which the sample is to be drawn which has been estimated to 
be 184,700 community pharmacists.  This estimate was determined by combining the National 
Community Pharmacists Association’s (NCPAs) estimate of 66,700 independent pharmacists in 
the United States (National Community Pharmacists Association, 2012) and the National 
Association of Chain Drug Stores’ (NACDSs) estimate of 118,000 chain pharmacists in the 
United States (National Association of Chain Drug Stores, 2012).  The term (p)(1-p) is a 
measure of the expected variation in answers to the question of interest (i.e. set at 50% which is 
the most conservative value possible for the population).  The term B represents the margin of 
error which is taken as 0.05.  Finally, C is the corresponding Z score associated with the amount 
of statistical confidence one desires to have in the estimate (commonly set at 95% and thus 1.96 
would be the corresponding Z score).  The estimated sample size was determined to be 383 
respondents when the population variance is 0.5, the margin for sampling error is set at 5% and 
a 95% confidence interval is used (Dillman, Smyth & Christian, 2009).  
 In the second estimate, the sample size was determined using G*Power, a power analysis 
program (Buchner et al., 1997).  The estimate of sample size for a fixed-effects, one-way 
Analysis of Variance (ANOVA) using a medium effect size (0.25), α = 0.05 at power = 0.95 and 
five groups was 305.  Taking both sample size calculations into consideration, it was determined 
that the conservative estimate of 383 respondents would be needed. 
 Attempts were made to determine the response rate of a community pharmacist sample 
completing a self-administered web-based survey.  A study conducted by Barnard (2012) using 
a sample of community pharmacists yielded a usable response rate of 2.4%.  However, it is 
possible that the sensitivity of Barnard’s survey topic (interpersonal violence) resulted in the low 
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response rate.  Other web-based surveys conducted in a national sample of community 
pharmacists yield slightly higher response rates.  For example, a response rate of 10.8% was 
obtained by McKenny and his colleagues in a study to determine the beliefs and attitudes of 
pharmacists about the significance of heart disease and its treatments (McKenny et al., 2004).  
Given these varying response rates, it was determined that the self-administered web-based 
survey would be administered to the entire available panel of community pharmacists provided 
by Delta Marketing Dynamics (n=2800). 
Measures 
Objective 1.  To meet the first study objective, determinants of innovation within 
healthcare organizations were adapted from Fleuren, Wiefferink and Paulussen (2004).  
Using this framework, it was proposed that characteristics of the socio-political context, 
characteristics of the adopting pharmacist, characteristics of the pharmacy, and characteristics 
of the innovation would comprise community pharmacists’ attitudes toward expansion of the 
nonprescription class of drugs. 
To generate a pool of items for each construct, items were adapted from scales developed 
in previous literature by Hunt et al. (2010), Sega and Sullivan (2011), Prince and Pharo (2008), 
Karst (2012) and the Department of Health and Human Services February 2012 Federal 
Register Notice.  Additionally, items were developed by the investigator.  The pool of items 
was categorized by the investigator into each framework component (socio-political, pharmacy, 
pharmacist, and innovation). The initial pool contained 36 items (Appendix 1). The attitudes of 
community pharmacists toward an expanded nonprescription class of drugs were assessed 
using a 7-point linear numeric scale. 
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In-depth cognitive interviews were conducted with six local pharmacists with 
community practice experience.  They were asked to provide feedback about each item’s 
relevance, clarity, and conciseness.  Also, they were asked to identify any other items that might 
be needed for the measure, in order to ensure comprehensiveness.  Following in-depth cognitive 
interviews, the items (and the survey in its entirety) were assessed for content validity by 
pharmacy administration graduate students at the University of Mississippi.  The graduate students 
were asked to note the time taken to complete the survey.  Any necessary refinements to the 
survey were made. The survey was also pre-tested among community pharmacists in the state of 
Mississippi and Doctor of Pharmacy students at the University of Mississippi Medical Center in 
Jackson, Mississippi.  
Objective 2. To meet the second objective, data was collected for twelve demographic 
and practice variables which included: 1) type of practice setting, 2) location of community 
pharmacy (rural or urban), 3) state in which the practice is located, 4) daily prescription volume 
for the pharmacy, 5) degrees earned, 6) years actively practicing pharmacy, 7) position in the 
pharmacy (staff, manager, etc.), 8) age, 9) gender, 10) race/ethnicity, 11) daily prescription 
volume for the individual pharmacist, and 12) pharmacy association affiliation.  Perceived 
workload was measured using a perceived role overload scale that was previously used in a 
sample of retail chain pharmacists with a Cronbach’s alpha of 0.92 (Holmes, 2008).  
Objective 3. To meet the third objective, the survey contained a list of current 
“prescription-only” drugs which may be potential candidates for an expanded nonprescription 
class of drugs based on criteria outlined in the February 2012 Federal Register, “Using 
innovative technologies and other conditions of safe use to expand which drug products can be 
considered nonprescription” (Department of Health and Human Services, 2012).  The 
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respondents were asked to indicate whether the particular drug should be marketed as a prescription 
drug, nonprescription drug or dual marketed as both prescription and nonprescription under the new 
paradigm. Input was obtained from the literature (Sega & Sullivan, 2011) and content experts (two 
pharmacists and a pharmacy student) to develop this drug list.  
Data Collection 
The data collection instrument proposed for this study was a web-based self-
administered survey.  The survey was programmed and distributed using Qualtrics, a web-
based tool used for survey design and distribution.  The modified Dillman tailored design 
method was adapted for use in this study to reduce survey error (Dillman, Smyth & Christian, 
2009). 
IRB approval was obtained before the data collection process was started. To send the 
final survey (Appendix 2) to the full study sample, the URL link to the survey was emailed to 
2800 pharmacists via Qualtrics.  The same email also contained a cover letter (Appendix 3) 
which provided details about the nature and purpose of the study.  All respondents were 
notified that their participation in the survey was voluntary and that their responses as well 
as private demographic information would be kept confidential.  Respondents were not forced 
to answer any question on the survey.  A screener question was included at the start of the 
survey to ensure that only community pharmacists answered the survey. An email 
expressing appreciation was sent out to all the responders at the end of the data collection 
period.  Respondents were incentivized by offering them an executive summary of the results 
and implications of the study. A similar procedure was also followed for the pre-test.  
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Data Management 
Data for responses from community pharmacists were obtained in the form of Microsoft 
Excel® file (*.xls).  Responses to the survey were automatically recorded electronically as the 
respondents completed their survey.  Data were cleaned in Microsoft Excel® before being 
analyzed using Statistical Package for Social Sciences IBM (SPSS®) version 20.0 for 
Windows®.  Observations with 15% or more data missing were excluded from analysis to 
avoid omitted data bias (Hair et al., 1998). 
Data Analysis 
Sample description.  The description of the sample was provided using the twelve 
demographic variables previously discussed by calculating appropriate means, frequencies and 
percentages as appropriate. 
Objective 1.  Initially, a principal component analysis (PCA) using VARIMAX rotation 
was performed for all pharmacist attitude items in order to define a set of underlying dimensions 
or factors, of pharmacist attitudes, despite the theoretical framework used to develop the items. 
To examine reliability, item-total correlations and Cronbach’s alpha were calculated for each of 
these subscales.  Means, standard deviations, and per item means were calculated for each 
subscale to meet the first objective of determining community pharmacists’ attitudes toward a 
nonprescription drug class as a “new paradigm”.  
Objective 2.  Multivariate Analysis of Variance (MANOVA) (depending on whether 
variables contained two or more levels for comparison) were carried out to assess significant 
differences between and among levels of demographic variables (i.e. type of practice setting, 
location of community pharmacy, region in which the practice is located, degrees earned, 
position in the pharmacy, pharmacy association affiliation) for each of the four attitude 
subscales.  Before conducting analyses, assumptions of homogeneity of variance-covariance 
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matrices, independence, linearity and existence were tested. The level of significance used for 
these tests was α = 0.05. 
Correlation coefficients were calculated to test the degree of correlation between the 
perceptions of workload scale and the four attitude subscales. This procedure was repeated for 
testing the degree of correlation between years of actively practicing pharmacy and the four 
attitude subscales. 
Objective 3.  Frequencies were calculated in order to determine the number of 
pharmacists that appropriated the sale of a particular drug under each of the three categories (i.e. 
prescription-only, nonprescription, and both prescription and nonprescription).  
Nonresponse bias.  A time-trends extrapolation method was used to determine the 
nonresponse bias by comparing the responses of the first and last 20% of survey respondents on 
demographics and practice characteristics. The assumption underlying this test is that 
individuals who respond later to a questionnaire are similar to those who do not respond at all 
(Armstrong & Overton, 1977).  Independent sample t-tests and chi-square tests were conducted 
to determine if differences in demographic and practice variables existed between these two 
groups.   
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RESULTS 
Sample Description 
Participant Response. A total of 462 completed, useable responses were obtained. 
Participants were eligible for the study only if they were community pharmacists (potential 
respondents were screened at the start of the survey). Initially, 616 responses were obtained. 
However, participants who were missing more than 15% (Hair et al., 1998) (i.e. more than four 
questions) of their responses on the attitude scale were excluded from analysis. 
Respondent Demographics. The average age of the respondents was 49 years. The sample 
consisted of 272 males (61.4%) and 171 females (38.6%). The sample was predominantly 
Caucasian (87.2%). Just over 66% of respondents had a Bachelor of Pharmacy (BPharm; 
practice degree) while almost 28% had a Doctor of Pharmacy (PharmD). 297 (64.28%) 
respondents were affiliated with a national, state, or local professional pharmacy organization 
while 165 (35.72%) did not report membership with a pharmacy organization. A full description 
of respondents’ demographic characteristics is provided in Tables 1 and 2.  
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Table 1. Characteristics of Respondents 
Characteristics No. Respondents (%)* 
 
Gender 
                    Men 
                    Women 
 
 
272 (61.4) 
171 (38.6) 
 
Race/Ethnicity 
                    White/Caucasian   
                    Asian/ Asian Indian 
                    Hispanic 
                    African American/Black 
                    American Indian/Alaska Native   
                    Other        
 
 
381 (87.2) 
32 (7.3) 
4 (0.9) 
9 (2.1) 
3 (0.7) 
8 (1.8) 
 
Pharmacy Training** 
                    Bachelor of Pharmacy (practice degree)                                          
                    Doctor of Pharmacy 
                    Master of Science  
                    Doctor of Philosophy 
                    Other                                                                      
 
 
320 (66.12)
133 (27.48) 
6 (1.24) 
3 (0.62)  
22 (4.54) 
 
Membership of Professional Pharmacy Organization** 
                     American Pharmacists Association 
                     National Community Pharmacists Association 
                     American Society of Health-System                 
                     Pharmacists 
                     National Pharmaceutical Association 
                     State Pharmacy Association 
                     Other  
 
 
 
118 (22.01) 
81 (15.14) 
9 (1.68) 
 
10 (1.87) 
226 (42.24) 
91 (17.01) 
 
*Categories may not add to the total of 462 useable responses due to missing demographic data. 
**Respondents could check all responses that applied. 
 
 
 
Table 2. Characteristics of Respondents and their Practices 
Characteristics Mean (Standard Deviation) Range 
Age 48.76 (11.27) 25-82 
Years of actively practicing pharmacy 23.59 (11.50) 1.5-60 
Number of hours practiced in a typical week 41.51 (7.81) 10-80 
Number of prescriptions store fills on an 
average weekday 
449.93 (554.26) 50-4500 
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Respondent Practice Characteristics. Most of the respondents were pharmacy managers/ 
pharmacists-in-charge (54.3%) and worked in an independent pharmacy (37.8%) in a self-
reported urban location (57.9%). The sample was representative of all four census regions in the 
United States (Census Bureau, 2013). On average, respondents reported to have been actively 
practicing pharmacy for nearly 24 years. In a typical week respondents worked an average of 
almost 42 hours. Respondents reported that their stores fill an average of 450 prescriptions on a 
typical weekday. A full description of respondents’ practice characteristics is provided in Tables 
2 and 3.  
Table 3. Characteristics of Respondents’ Practices 
Characteristics No. Respondents (%)* 
 
Type of Pharmacy 
                    Independent 
                    Franchise  
                    Traditional Chain 
                    Supermarket with a pharmacy 
                    Mass merchandiser with a pharmacy 
                    Other     
 
 
168 (37.8) 
23 (5.2) 
72 (16.2) 
130 (29.3) 
41 (9.2) 
10 (2.3) 
 
Position in the Pharmacy 
                    Staff/Floater/Relief pharmacist 
                    Manager/Pharmacist in-charge 
                    Owner 
                    District manager 
                    Regional manger 
                    Other        
 
 
128 (29.0) 
240 (54.3) 
70 (15.8) 
3 (0.7) 
0 (0.0) 
1 (0.2) 
 
Location of Pharmacy 
                    Urban                                          
                    Rural 
  
 
 
256 (57.9) 
186 (42.1) 
 
Geographic Region of practice 
                     South 
                     Mid-West  
                     North East 
                     West 
 
152 (34.1) 
104 (23.3) 
108 (24.2) 
82 (18.4) 
*Categories may not add to the total of 462 useable responses due to missing practice 
characteristic data. 
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Estimation of Nonresponse Bias  
Nonresponse bias was estimated using the time trends extrapolation technique (Armstrong 
& Overton, 1977). T-tests and chi-square tests were conducted to determine if significant 
differences in demographic and other variables existed between the first and last 10% of 
respondents. T-tests indicated significant differences between early and late responders’ age and 
years practicing (Table 4). Chi-square tests did not indicate significant differences in 
nonparametric data between early and late responders (Table 5). 
Table 4. Estimation of Nonresponse Bias: Time Trends Extrapolation of Parametric Data 
Variable Mean and Std 
Error 
First 10% 
(n=46)  
Last 10% 
(n=46) 
t-value    
 
p-value    
 
Patient care mean 
std error 
5.11 
0.19 
5.16 
0.19 -0.198 0.843 
Workflow mean 
std error 
5.30 
0.15 
5.27 
0.16 0.133 0.894 
Patient safety mean 
std error 
6.33 
0.13 
6.39 
0.11 -0.329 0.743 
Non-pharmacist 
providers 
mean 
std error 
4.62 
0.26 
4.48 
0.20 0.420 0.675 
Pharmacist burden mean 
std error 
6.61 
0.10 
6.63 
0.14 -0.124 0.901 
Access mean 
std error 
5.09 
0.15 
4.81 
0.18 1.212 0.229 
Age* mean 
std error 
44.47 
1.65 
49.52 
1.68 -2.153 0.034 
Number of years 
practicing* 
mean 
std error 
18.04 
1.52 
23.82 
1.73 -2.153 0.034 
Number of hours 
practiced in a typical 
week 
mean 
std error 
43.00 
1.36 
40.89 
1.37 1.097 0.276 
Number of prescriptions 
store fills on an average 
weekday 
mean 
std error 
423.52 
74.74 
457.5 
83.53 
-0.303 0.763 
Perceptions of workload mean 
std error 
3.03 
0.14 
3.22 
0.15 
-0.913 0.364 
*Significant at α = 0.05 
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Table 5. Estimation of Nonresponse Bias: Time Trends Extrapolation of Nonparametric 
Data 
Variable Category First 10% 
(n=50)  
Last 10% 
(n=50) 
    χ2              p-value             
Work 
location 
Urban 
Rural 
27 (61.4%) 
17 (38.6%) 
29 (65.9%) 
15 (34.1%) 
 0.196        0.906 
Store 
category 
Independent 
Chain 
14 (33.3%) 
28 (66.7%) 
15 (34.9%) 
28 (65.1%) 
0.177         0.915 
Position Staff/relief/floater 
PIC/manager 
Owner 
15 (34.9%) 
22 (51.2%) 
6 (13.9%) 
19 (44.2%) 
18 (41.9%) 
6(13.9%) 
0.871         0.833 
Geographic 
region of the 
country 
Northeast 
Midwest 
South 
West 
   13(29.5%) 
 9 (20.5%) 
11 (25%) 
   11(25%) 
14 (31.8%) 
10 (22.7%) 
 11 (25%) 
9 (20.5%) 
0.290         0.990 
Gender Male 
Female 
22 (50%) 
22 (50%) 
25 (56.8%) 
19 (43.2%) 
0.411         0.521 
Professional 
Organization 
Affiliation 
Yes 
No 
27 (%) 
16 (%) 
31 (%) 
12 (%) 
0.847         0.655 
Race American Indian 
Asian 
African American 
Hispanic 
Native Hawaiian 
White 
Other 
    0 (0%) 
    3 (7%) 
    0 (0%) 
1 (2.3%) 
    0 (0 %) 
   36 (83.7%) 
    3 (7%) 
  0 (0%) 
5 (11.4%) 
  2 (4.5%) 
  0 (0%) 
  0 (0%) 
37 (84.1%) 
  0 (0%) 
6.503         0.165 
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Objective 1 
The first objective for this study was to measure community pharmacists’ attitudes 
toward an expanded nonprescription drug class under the FDA’s proposed “new paradigm”. 
Principal Components Analysis. The scale used to measure community pharmacists’ 
attitude toward an expanded nonprescription drug class established under the “new paradigm” 
consisted of 37 items. The scale was a 7-point linear numeric scale where 1 = “Strongly 
Disagree” and 7 = “Strongly Agree”. These items were based on a thorough search of the 
literature and the theoretical framework for the study (Determinants of Innovation Framework) 
(Fleuren, Wiefferink, & Paulussen, 2004) but not from any established scale. Therefore a 
principal components analysis (PCA) with VARIMAX rotation was performed in order to 
identify the dimensions of community pharmacists’ attitudes toward the “new paradigm”.  
Although the scale initially had 37 items, eight items were removed after assessing factor 
loadings, cross loadings and communalities (as well as Cronbach’s alpha if deleted and item-to-
total correlations examined in the reliability analysis described below). Thus the final scale had 
only 29 items. The items which were deleted were: 
“Assuming the implementation of an expanded nonprescription drug class under the FDA’s 
proposed ‘new paradigm’……”  
1. Pharmacist intervention would still be needed if innovative technologies that help 
patients self-assess their drug choices are instituted under the "new paradigm". 
2. Patients would seek medical help more quickly than they do now. 
3. Additional pharmacist training would have to be provided by pharmacies if the "new 
paradigm" were instituted. 
4. The "new paradigm" would foster better physician-pharmacist relationships. 
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5. The "new paradigm" would foster better patient-pharmacist relationships. 
6. Patients would be capable of gauging their own health status using kiosks and online 
questionnaires. 
7. Adopting the "new paradigm" should be mandatory for all pharmacies. 
8. The profitability of a pharmacy would increase. 
As a result of this analysis, six components (i.e., underlying dimensions) were identified 
from the scale: patient care (9 components), workflow (6 items), patient safety (5 items), non-
pharmacist providers (3 items), pharmacist burden (3 items) and access (3 items). Standardized 
coefficients from the rotated factor matrix representing the loading of each item to the 
component to which it was assigned is shown in Table 6.   
Reliability. Reliabilities of the six components obtained from the PCA were calculated 
using Cronbach’s alpha.  Table 6 lists all six components and their associated items along with 
their Cronbach’s alpha coefficients, the summated means and standard deviations of the scale 
scores, and the per-item means for each scale. Cronbach’s alpha of the overall scale was 0.786 
with summated mean and standard deviation of 157.907 ± 16.21 after the deletion of the above-
mentioned eight items.  
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Table 6. Principal Component Analysis and Reliability Results 
Items* Number of Items 
Standardized 
Coefficients   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Cronbach's 
Alpha Means ± SD 
Per-
Item 
Mean 
Component 1 – Patient Care 9  0.888 46.539 ± 10.62 5.17 
Pharmacists would have time to assist patients in selecting the most 
appropriate “new paradigm” drug 
 
0.696 
  
3.91 
Pharmacist-authorized refills following a physician’s initial prescription 
should be permitted under the new paradigm 0.740 5.35 
Pharmacists would be comfortable enough to order diagnostic/lab tests before 
dispensing certain “new paradigm” medications 0.740 4.65 
Pharmacists are capable enough to order diagnostic/lab tests before dispensing 
certain “new paradigm” medications 0.704 5.11 
Pharmacists have the ability to make appropriate treatment recommendations 0.660 6.50 
The “new paradigm” would allow for more patient-directed care 0.533 6.10 
I support the institution of the “new paradigm” in pharmacy practice. 0.853 5.33 
Patient medication adherence would improve 0.600 4.85 
Patients would be accepting of pharmacists monitoring their treatment 0.588 5.35 
Component 2 – Workflow 6  0.816 31.088 ± 6.90 5.18 
Significant structural changes would have to be made in pharmacies to 
incorporate extra space for patient consulting rooms 
 
0.767 
  
5.64 
Significant structural changes would have to be made in pharmacies to 
incorporate extra space for an expanded nonprescription drug section under the 
“new paradigm” 
0.788 5.03 
The number of personnel in pharmacies would have to be increased if the “new 
paradigm” were instituted 0.780 5.67 
Significant changes in workflow of the pharmacy would have to be made 0.749 5.79 
It would be difficult to implement the “new paradigm” in a typical community 
pharmacy setting 0.580 4.17 
The installation of innovative technologies such as kiosks and online 
questionnaires in pharmacies would be problematic 0.457 4.80 
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Items* Number of Items 
Standardized 
Coefficients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cronbach's 
Alpha Means ± SD 
Per-
Item 
Mean 
Component 3 – Patient safety 5  0.769 32.163 ± 3.97 6.43 
When in doubt, pharmacists should refer patients to a physician before 
dispensing a “new paradigm” medication 
 
0.682 
  
6.44 
Pharmacists should alert a physician if there are problems with “new 
paradigm” medications that a patient is taking 0.750 6.62 
Patient counseling by pharmacists for “new paradigm” medications should be 
mandatory 0.683 6.32 
Pharmacists should document the “new paradigm” medication history of a 
patient 0.738 6.50 
Pharmacists should have access to patient medical records to dispense “new 
paradigm” medications 0.665 6.29 
Component 4 – Non-pharmacist providers 3  0.809 13.463 ± 4.39 4.49 
Physician workload would be reduced 
 
0.796 
  
4.84 
Primary care physician shortages would be reduced 0.802 4.28 
The burden on emergency rooms would be reduced 0.762 4.34 
*All items were preceded by the statement, “Assuming the implementation of an expanded nonprescription drug class under the FDA’s proposed 
‘new paradigm’……”  Items were measured on a 7-point linear numeric scale where 1 = Strongly Disagree and 7 = Strongly Agree. 
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Items* Number of Items 
Standardized 
Coefficients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cronbach's 
Alpha Means ± SD 
Per-
Item 
Mean 
Component 5 – Pharmacist burden 3  0.705 19.920 ± 1.87 6.64 
Pharmacists should be reimbursed for the time they spend diagnosing and 
counseling a patient for “new paradigm” medications 
 
0.463 
  
6.76 
The professional liability of a pharmacist would increase 0.844 6.55 
Pharmacist workload would  increase 0.794 6.62 
Component 6 – Access 3  0.472 14.734 ± 3.32 4.91 
Pharmacy shopping among patients would increase 
 
0.640 
  
4.36 
Patients would have increased access to medications 0.555 5.72 
There would be an increase in out-of-pocket drug expenditures for insured 
patients under the “new paradigm” 0.704 4.65 
*All items on the scale start off as “Assuming the implementation of an expanded nonprescription drug class under the FDA’s proposed ‘new 
paradigm’……”  Items were measured on a 7-point linear numeric scale where 1 = Strongly Disagree and 7 = Strongly Agree. 
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Objective 2 
Overview. The second objective of this study was to determine if attitudes of community 
pharmacists toward an expanded nonprescription drug class under the FDA’s proposed “new 
paradigm” differed by 1) type of practice setting, 2) location of community pharmacy, 3) 
geographic region, 4) degrees earned, 5) years actively practicing pharmacy, 6) position in the 
pharmacy, 7) perceived workload, and 8) pharmacy association affiliation. 
Multivariate analysis of variance (MANOVA) was conducted to test the six categorical 
independent variables (type of practice setting, location of community pharmacy, geographic 
region, degrees earned, position in the pharmacy, and pharmacy association affiliation).  
Correlations were conducted to test the two continuous independent variables (years actively 
practicing pharmacy and perceived workload).  The dependent variables for each of the models 
were the six components of community pharmacists’ attitudes toward an expanded 
nonprescription drug class established under the “new paradigm”. These components were 
previously identified using a PCA with VARIMAX rotation. The scores on these components for 
each community pharmacist were calculated as average scores for all the survey items which 
loaded under that particular component (See Table 6, above) (Hair et al., 1998).   
Three assumptions of the MANOVA design which were essential for the MANOVA 
procedure to be valid were (Hair et al., 1998): 
• Independence of the observations – This assumption requires that the dependent 
measures for each respondent be totally uncorrelated with the responses from 
other respondents in the sample. A lack of independence affects the statistical 
validity of the MANOVA and this is the most important assumption that must be 
met. 
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• Homogeneity of the variance-covariance matrices – This assumption is the 
multivariate equivalent of the assumption of homogeneity of variance in the 
ANOVA design. Meeting this assumption ensures that there are no substantial 
differences in the amount of variance for one group versus another for the 
dependent variable of interest. In the null form this assumption can be stated as  
H0: ∑1 = ∑2 = ∑3 =…. = ∑k 
This assumption was tested using the Box’s M test. Although this assumption is 
prone to violations, MANOVA is robust to the violations of this assumption as 
long as the group sizes are roughly equal. 
• Multivariate Normality - Multivariate normality holds when, and only when, any 
linear combination of the individual variables involved is univariate normal (i.e., 
testing for multivariate normality per se is not practically possible, since it 
involves infinitely many tests). This assumption must be met for the computation 
of hypothesis tests. 
Type of Practice Setting. The independent variable of interest for the first MANOVA was 
the type of pharmacy in which the community pharmacist worked. This variable was 
dichotomized into 1) independent pharmacy and 2) chain pharmacy. The initial six categories for 
this variable were collapsed into two due to the small number of respondents in some levels of 
this variable. Independent and franchise pharmacies were combined to create an independent 
pharmacy level, while traditional chain, supermarket with a pharmacy and mass merchandiser 
with a pharmacy were combined to create a chain pharmacy level. The results for this 
MANOVA are shown in Table 7.   
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Results of this analysis indicated that there were significant differences in attitudes 
toward an expanded nonprescription drug class under the “new paradigm”, between pharmacists 
from independent and chain pharmacy settings with respect to patient care and workflow. 
Pharmacists working in independent pharmacies more strongly agreed with patient care 
statements (means: 5.32 versus 5.05) and pharmacists working in chain pharmacies more 
strongly agreed with workflow statements (means: 5.39 versus 4.96). Table 8 provides the means 
for the two groups on each component of attitude (i.e., each DV). 
 
 
Table 7. MANOVA Results for Objective 2 
Independent Variable: Type of Pharmacy 
 
  Sum of 
Squares 
df Mean Square F Sig. 
Patient care* 
Between Groups 7.541 1 7.541 5.404 0.021 
Within Groups 605.602 434 1.395   
Total 613.143 435    
Workflow* 
Between Groups 20.627 1 20.627 16.223 <0.0005 
Within Groups 551.829 434 1.271   
Total 572.456 435    
Patient safety 
Between Groups 0.045 1 0.045 0.080 0.777 
Within Groups 244.751 434 0.564   
Total 244.796 435    
Non-pharmacist 
providers 
Between Groups 0.505 1 0.505 0.239 0.625 
Within Groups 917.851 434 2.115   
Total 918.356 435    
Pharmacist 
burden 
Between Groups 1.011 1 1.011 2.577 0.109 
Within Groups 170.189 434 0.392   
Total 171.2 435    
Access 
Between Groups 1.274 1 1.274 1.056 0.305 
Within Groups 523.294 434 1.206   
Total 524.568 435    
*Significant at α = 0.05 
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Table 8. Means of Attitudes Based on Respondents’ Practice Type 
 
 
 
 
 
 
 
 
 
 
 
 
*Measured on a 7-point linear numeric scale where 1=Strongly Disagree and 7=Strongly Agree. 
 
Factors* 
Group 1 
Independent 
Pharmacy 
Group 2 
Chain 
Pharmacy 
Total 
 N = 193 N = 243 N = 436 
 MEAN SD MEAN SD MEAN SD 
Patient care 5.32 1.14 5.05 1.22 5.17 1.19 
Workflow 4.96 1.15 5.39 1.11 5.20 1.15 
Patient safety 6.45 0.76 6.47 0.75 6.46 0.75 
Non-
pharmacist 
providers 
4.44 1.41 4.51 1.49 4.48 1.45 
Pharmacist 
burden 6.59 0.56 6.69 0.68 6.64 0.63 
Access 4.86 0.98 4.96 1.18 4.91 1.10 
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Affiliation with a Professional Organization. The independent variable of interest for the 
second MANOVA was affiliation to a professional pharmacy organization. The independent 
variable had two levels: member of professional pharmacy organization or not a member of 
professional pharmacy organization. The results for this MANOVA are shown in Table 9. It 
should be noted that there were significant differences in attitudes toward an expanded 
nonprescription drug class between the members of a pharmacy organization and nonmembers 
with respect to patient care and workflow. Pharmacists affiliated with a professional organization 
more strongly agreed with patient care statements (means: 5.32 versus 4.90) and pharmacists not 
affiliated with a professional organization more strongly agreed with workflow statements 
(means: 5.35 versus 5.09). Table 10 displays the means for the two groups on each component of 
attitude (i.e., each dependent variable). 
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Table 9. MANOVA Results for Objective 2 
Independent Variable: Affiliation to a Professional Organization 
 
  Sum of 
Squares 
df Mean Square F Sig. 
Patient care* 
Between Groups 18.616 1 18.616 13.751 <0.0005 
Within Groups 622.727 460 1.354   
Total 641.343 461    
Workflow* 
Between Groups 7.397 1 7.397 5.655 0.018 
Within Groups 601.685 460 1.308   
Total 609.082 461    
Patient safety 
Between Groups 1.672 1 1.672 2.663 0.103 
Within Groups 288.811 460 0.628   
Total 290.483 461    
Non-pharmacist 
providers  
Between Groups 2.258 1 2.258 1.055 .0.305 
Within Groups 984.506 460 2.140   
Total 986.764 461    
Pharmacist 
burden 
Between Groups 0.428 1 0.428 1.099 0.295 
Within Groups 179.132 460 0.389   
Total 179.56 461    
Access 
Between Groups 3.914 1 3.914 3.207 0.074 
Within Groups 561.381 460 1.220   
Total 565.295 461    
*Significant at α = 0.05 
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 Table 10. Means of Attitudes Based on Affiliation with a Professional Organization  
 
 
 
 
 
 
 
 
 
 
 
 
*Measured on a 7-point linear numeric scale where 1=Strongly Disagree and 7=Strongly Agree.
Factors* Group 1 No affiliation 
Group 2 
Affiliated to at 
least one 
organization 
Total 
 N = 165 N = 297 N = 462 
 MEAN SD MEAN SD MEAN SD 
Patient Care 4.90 1.126 5.32 1.18 5.17 1.18 
Workflow 5.35 1.07 5.09 1.18 5.18 1.15 
Patient safety 6.35 0.80 6.48 0.79 6.43 0.79 
Non-
pharmacist 
providers 
4.39 1.35 4.54 1.52 4.49 1.46 
Pharmacist 
burden 6.68 0.53 6.62 0.67 6.64 0.62 
Access 5.03 1.08 4.84 1.12 4.91 1.11 
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Location of Community Pharmacy. The independent variable of interest for the third 
MANOVA was the location of the community pharmacy. The independent variable had two 
levels: rural and urban (self-reported by the respondents). The results for this MANOVA are 
shown in Table 11. There were no significant differences between the two groups.  
 
Table 11. MANOVA Results for Objective 2 
Independent Variable: Location of Pharmacy 
 
  Sum of 
Squares 
df Mean Square F Sig. 
Patient care 
Between Groups 0.499 1 0.499 .356 0.551 
Within Groups 615.561 440 1.399   
Total 641.343 441    
Workflow 
Between Groups 3.282 1 3.282 2.514 0.114 
Within Groups 574.471 440 1.306   
Total 609.082 441    
Patient safety 
Between Groups 0.511 1 0.511 0.901 0.343 
Within Groups 249.640 440 0.567   
Total 290.483 441    
Non-pharmacist 
providers 
Between Groups 0.797 1 0.797 0.382 0.537 
Within Groups 917.492 440 2.085   
Total 986.764 441    
Pharmacist 
burden 
Between Groups 0.112 1 0.112 0.282 0.596 
Within Groups 174.988 440 0.398   
Total 179.56 441    
Access 
Between Groups 3.798 1 3.798 3.072 0.080 
Within Groups 543.971 440 1.236   
Total 565.295 441    
*Significant at α = 0.05 
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 Table 12. Means of Attitudes Based on Location of Pharmacy  
 
 
 
 
 
 
 
 
 
 
 
*Measured on a 7-point linear numeric scale where 1=Strongly Disagree and 7=Strongly Agree.
Factors* Group 1 Rural 
Group 2 
Urban Total 
 N = 186 N = 256 N = 442 
 MEAN SD MEAN SD MEAN SD 
Patient Care 5.15 1.21 5.21 1.14 5.18 1.18 
Workflow 5.26 1.13 5.09 1.17 5.19 1.14 
Patient safety 6.48 0.79 6.41 0.70 6.45 0.75 
Non-
pharmacist 
providers 
4.51 1.47 4.43 1.41 4.48 1.44 
Pharmacist 
burden 6.65 0.61 6.62 0.66 6.64 0.63 
Access 4.98 1.11 4.80 1.12 4.90 1.11 
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Region of Practice. The independent variable of interest for the fourth MANOVA was 
region of practice which was determined based on the state of practice of the respondent as 
indicated on the survey. The independent variable had four levels which were the four regions of 
the United States based on Census Bureau designations. These regions were Northeast, Midwest, 
South and West. The results for this MANOVA are shown in Table 13.   
The results from the MANOVA suggested that significant differences existed between 
the groups with respect to patient care. Pharmacists from western states more strongly agreed 
with patient care statements than pharmacists from northeastern states. In order to more 
specifically examine these differences, post-hoc tests were conducted using Tukey’s post-hoc 
tests.  The results from the post-hoc analysis suggest that significant differences existed between 
the northeast (4.90 ± 1.22) and the west (5.38 ± 1.14) with respect to patient care under the new 
paradigm (p = 0.028).  Means of the attitude components are provided in Table 14.  No other 
significant differences existed among the four regions of the country.
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Table 13. MANOVA Results for Objective 2 
Independent variable: Region of Practice 
 
  Sum of 
Squares 
Df Mean Square F Sig. 
Patient care* 
Between Groups 12.829 1 12.829 3.118 0.026 
Within Groups 606.120 442 1.371   
Total 618.949 443    
Workflow 
Between Groups 3.143 1 3.143 0.803 0.493 
Within Groups 576.793 442 1.305   
Total 579.936 443    
Patient safety 
Between Groups 3.037 1 3.037 1.807 0.145 
Within Groups 247.625 442 0.560   
Total 250.662 443    
Non-pharmacist 
providers 
Between Groups 8.532 1 8.532 1.353 0.257 
Within Groups 928.904 442 2.102   
Total 937.436 443    
Pharmacist 
burden 
Between Groups 2.404 1 2.404 2.045 0.107 
Within Groups 173.213 442 0.392   
Total 175.617 443    
Access 
Between Groups 3.536 1 3.536 0.949 0.417 
Within Groups 548.811 442 1.242   
Total 552.347 443    
*Significant at α = 0.05 
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 Table 14. Means of Attitudes Based on Region of Practice 
*Measured on a 7-point linear numeric scale where 1=Strongly Disagree and 7=Strongly Agree. 
 
 
Factors* Group 1 Northeast 
Group 2 
Midwest 
Group 3 
South 
Group 4 
West Total 
 N = 108 N = 104 N = 152 N = 82 N = 462 
 MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD 
Patient care 4.90 1.22 5.22 1.08 5.26 1.21 5.38 1.14 5.18 1.18 
Workflow 5.31 1.16 5.25 1.06 5.13 1.23 5.10 1.04 5.19 1.14 
Patient safety 6.36 0.93 6.52 0.53 6.41 0.80 6.58 0.60 6.45 0.75 
Non-
pharmacist 
providers 
4.34 1.48 4.34 1.46 4.62 1.44 4.61 1.41 4.49 1.45 
Pharmacist 
burden 6.72 0.63 6.66 0.50 6.54 0.80 6.69 0.44 6.64 0.63 
Access 5.07 1.05 4.86 1.13 4.86 1.14 4.85 1.11 4.91 1.11 
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Pharmacy Position. The IV of interest for the fifth MANOVA was position in the 
pharmacy. The independent variable had three levels for analysis which were staff/relief/floater 
pharmacist, pharmacy manager/pharmacist-in-charge and pharmacy owner. The categories of 
district manager, regional manager and other were excluded from the analysis due to the small 
number of respondents in these categories. The results for this MANOVA are shown in Table 15. 
The results from the MANOVA suggested that significant differences existed between 
the groups with respect to patient care and workflow. Pharmacy owners (5.48 ± 1.19) and 
managers (5.23 ± 1.12) more strongly agreed with patient care statements then staff pharmacists 
(4.91 ± 1.21).  Staff pharmacists (5.39 ± 1.02) and pharmacy managers (5.22 ± 1.14) more 
strongly agreed with workflow statements than pharmacy owners (4.76 ± 1.26). To more 
specifically examine these differences, post-hoc tests were conducted using Tukey’s post-hoc 
tests.  With respect to patient care, significant differences were observed between 
staff/relief/floater pharmacists and pharmacy managers/pharmacists-in-charge (p = 0.033), and 
staff/relief/floater pharmacists and pharmacy owners (p = 0.004). With respect to workflow, 
significant differences were observed between staff/relief/floater pharmacists and pharmacy 
owners (p = 0.007), and pharmacy managers/pharmacists-in-charge and pharmacy owners (p = 
0.001). Means of the attitude scale components are provided in Table 16.   
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Table 15. MANOVA Results for Objective 2 
Independent Variable: Pharmacy Position 
 
  Sum of 
Squares 
Df Mean Square F Sig. 
Patient care* 
Between Groups 15.841 2 7.921 5.878 0.003 
Within Groups 586.203 435 1.348   
Total 602.044 437    
Workflow* 
Between Groups 18.222 2 9.111 7.169 0.001 
Within Groups 552.820 435 1.271   
Total 571.042 437    
Patient safety 
Between Groups 1.500 2 0.750 1.341 0.263 
Within Groups 243.392 435 0.560   
Total 244.892 437    
Non-pharmacist 
providers 
Between Groups 4.287 2 2.143 1.032 0.357 
Within Groups 903.533 435 2.077   
Total 907.82 437    
Pharmacist 
burden 
Between Groups 1.116 2 0.558 1.418 0.243 
Within Groups 171.163 435 0.393   
Total 172.279 437    
Access 
Between Groups 6.284 2 3.142 2.530 0.081 
Within Groups 540.236 435 1.242   
Total 546.52 437    
*Significant at α = 0.05 
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 Table 16. Means of Attitudes Based on Pharmacy Position 
*Measured on a 7-point linear numeric scale where 1=Strongly Disagree and 7=Strongly Agree. 
 
Factors* 
Group 1 
Staff/Relief/Floater 
Pharmacist 
Group 2 
Pharmacy 
Manager/Pharmacist 
in-charge 
Group 3 
Pharmacy 
Owner 
Total 
 N = 128 N = 240 N = 70 N = 438 
 MEAN SD MEAN SD MEAN SD MEAN SD 
Patient care 4.91 1.21 5.23 1.12 5.48 1.19 5.18 1.17 
Workflow 5.39 1.02 5.22 1.14 4.76 1.26 5.19 1.14 
Patient safety 6.44 0.81 6.43 0.75 6.59 0.66 6.45 0.75 
Non-
pharmacist 
providers 
4.39 1.37 4.56 1.43 4.32 1.62 4.47 1.44 
Pharmacist 
burden 6.64 0.74 6.68 0.57 6.53 0.58 6.64 0.63 
Access 5.05 1.17 4.91 1.11 4.68 1.03 4.91 1.12 
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Highest Pharmacy Degree Earned. The independent variable of interest for the sixth 
MANOVA was highest pharmacy degree earned. The independent variable had two levels; 
Bachelor of Pharmacy (BPharm) and Doctor in Pharmacy (PharmD). The other three categories 
Master of Science (MS), Doctor of Philosophy (PhD) and other were not included in the analysis 
due to the small number of respondents in these categories. For the purposes of this analysis, 
community pharmacists who had both a BPharm and PharmD were only included in the PharmD 
category. The results for this MANOVA are shown in Table 17.  It should be noted from the 
table below that there were significant differences in patient care and non-pharmacist provider 
attitudes between community pharmacists who had BPharm only compared to community 
pharmacists who had a PharmD. Pharmacists with a PharmD more strongly agreed with patient 
care (means: 5.41 versus 5.07) and non-pharmacist provider (means: 4.84 versus 4.32) 
statements. Means of attitude components may be found in Table 18.
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Table 17. MANOVA Results for Objective 2 
Independent Variable: Highest Pharmacy Degree Earned  
 
  Sum of 
Squares 
Df Mean Square F Sig. 
Patient care* 
Between Groups 10.612 1 10.612 7.686 0.006 
Within Groups 603.324 437 1.381   
Total 613.936 438    
Workflow 
Between Groups 0.018 1 0.018 0.014 0.906 
Within Groups 575.154 437 1.316   
Total 575.172 438    
Patient safety 
Between Groups 0.294 1 0.294 0.515 0.473 
Within Groups 249.158 437 0.57   
Total 249.452 438    
Non-pharmacist 
providers* 
Between Groups 25.563 1 25.563 12.657 <0.0005 
Within Groups 882.603 437 2.020   
Total 908.166 438    
Pharmacist 
burden 
Between Groups 0.371 1 0.371 0.939 0.333 
Within Groups 172.763 437 0.395   
Total 173.134 438    
Access 
Between Groups 2.090 1 2.090 1.681 0.195 
Within Groups 543.487 437 1.244   
Total 545.577 438    
*Significant at α = 0.05 
 
 
 
 
 
 
 
 
 
 
52 
 
 Table 18. Means of Attitudes Based on Highest Pharmacy Degree Earned 
 
 
 
 
 
 
 
 
 
 
 
*Measured on a 7-point linear numeric scale where 1=Strongly Disagree and 7=Strongly Agree.
Factors* Group 1 B.S. Pharm. 
Group 2 
Pharm.D. Total 
 N = 306 N = 133 N = 439 
 MEAN SD MEAN SD MEAN SD 
Patient care 5.07 1.19 5.41 1.14 5.17 1.18 
Workflow 5.20 1.15 5.18 1.13 5.19 1.15 
Patient safety 6.43 0.76 6.49 0.74 6.45 0.75 
Non-
pharmacist 
providers 
4.32 1.43 4.84 1.40 4.48 1.44 
Pharmacist 
burden 6.62 0.65 6.68 0.59 6.64 0.63 
Access 4.86 1.11 5.01 1.13 4.91 1.12 
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Years of Practice and Workload. In order to assess whether attitudes of community 
pharmacists’ toward the new paradigm differed based on the number of years of practice or 
perceptions of their own workload, correlations between attitude components and each of these 
dependent variables were computed. These correlations can be found in the correlation matrix of 
variables in Table 19.   
Number of years of practicing pharmacy was found to be significantly and negatively 
correlated with non-pharmacist providers (r = -0.139, p = 0.004) and access (r = -0.104, p = 
0.029). The greater the number of years that respondents practiced pharmacy, the more likely 
they were to disagree with non-pharmacist provider statements and access statements. 
Perceptions of pharmacists’ workload were found to be significantly and positively correlated 
with workflow (r = 0.255, p < 0.0005). The greater the respondents’ perceived workload, the 
more likely they were to agree with workflow statements.
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Table 19. Correlation Matrix of Variables 
Variables Mean S.D. 1 2 3 4 5 6 7 8 9 10 
1. Patient care 5.17 1.18 1 -.380** .326** .522** -.018 -.017 -.016 .134** -.111* .170** 
2. Workflow 5.18 1.15 -.380** 1 .045 -.169** .339** .309** -.079 -.072 .190** -.110* 
3. Patient safety 6.43 0.79 .326** .045 1 .151** .354** .157** .026 .067 .014 .076 
4. Non-pharmacist providers 4.49 1.46 .522** -.169** .151** 1 .008 .026 -.139** .084 .023 .048 
5. Pharmacist burden 6.64 0.62 -.018 .339** .354** .008 1 .291** -.089 -.053 .077 -.049 
6. Access 4.91 1.1 -.017 .309** .157** .026 .291** 1 -.104* -.065 .049 -.083 
7. Number of years of 
practice 23.72 11.47 -.016 -.079 .026 -.139
** -.089 -.104* 1 -.068 -.130** .156** 
8. Region of practice -  -  .134** -.072 .067 .084 -.053 -.065 -.068 1 -.009 -.048 
9. Type of pharmacy -  -  -.111* .190** .014 .023 .077 .049 -.130** -.009 1 -.306** 
10. Membership of 
pharmacy organization 
-  -  .170** -.110* .076 .048 -.049 -.083 .156** -.048 -.306** 1 
11.  Gender -  -  -.112* .210** .035 .030 .108* .179** -.288** -.059 .137** -.135** 
12. Age 48.76 11.27 .011 -.101* .039 -.117* -.102* -.128** .938** -.017 -.124** .143** 
13. Highest pharmacy 
degree earned 
-  -  .131** -.006 .034 .168** .046 .062 -.638** .182** .122* -.085 
14. Location of pharmacy -  -  .028 -.075 -.045 -.029 -.025 -.083 -.076 .084 -.212** .057 
15. Number of hours 
practiced in a typical week 41.51 7.81 .153
** -.154** -.036 .010 -.048 -.055 -.081 .017 -.206** .187** 
16. Number of prescriptions 
store fills on an average 
weekday 
449.93 554.26 .027 .016 -.004 .030 .053 -.032 -.061 .025 .084 .031 
17. Position in the pharmacy -  -  .161** -.167** .054 .001 -.037 -.105* .249** -.035 -.432** .277** 
18. Perceptions of workload 3.22 0.97 -.064 .255** .006 -.062 .049 .038 .031 .012 .108* -.044 
**Correlation is significant at the 0.01 level (2-tailed).     *Correlation is significant at the 0.05 level (2-tailed). 
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Variables Mean S.D. 
11 12 13 14 15 16 17 18 
1. Patient care 5.17 1.18 -.112
* .011 .131** .028 .153** .027 .161** -.064 
2. Workflow 5.18 1.15 .210
** -.101* -.006 -.075 -.154** .016 -.167** .255** 
3. Patient safety 6.43 0.79 .035 .039 .034 -.045 -.036 -.004 .054 .006 
4. Non-pharmacist providers 4.49 1.46 .030 -.117
* .168** -.029 .010 .030 .001 -.062 
5. Pharmacist burden 6.64 0.62 .108
* -.102* .046 -.025 -.048 .053 -.037 .049 
6. Access 4.91 1.1 .179
** -.128** .062 -.083 -.055 -.032 -.105* .038 
7. Number of years of practice 23.72 11.47 -.288
** .938** -.638** -.076 -.081 -.061 .249** .031 
8. Region of practice -  -  -.059 -.017 .182
** .084 .017 .025 -.035 .012 
9. Type of pharmacy -  -  .137
** -.124** .122* -.212** -.206** .084 -.432** .108* 
10. Membership of pharmacy 
organization 
-  -  -.135** .143** -.085 .057 .187** .031 .277** -.044 
11.  Gender -  -  1 -.290
** .137** -.067 -.243** -.035 -.251** -.063 
12. Age 48.76 11.27 -.290
** 1 -.584** -.059 -.072 .023 .260** .022 
13. Highest pharmacy degree 
earned 
-  -  .137** -.584** 1 -.065 .057 .020 -.204** -.014 
14. Location of pharmacy -  -  -.067 -.059 -.065 1 .025 -.010 .150
** -.050 
15. Number of hours practiced in 
a typical week 41.51 7.81 
-.243** -.072 .057 .025 1 .014 .377** .043 
16. Number of prescriptions store 
fills on an average weekday 449.93 554.26 
-.035 .023 .020 -.010 .014 1 -.081 .127** 
17. Position in the pharmacy -  -  -.251
** .260** -.204** .150** .377** -.081 1 -.033 
18. Perceptions of workload 3.22 0.97 -.063 .022 -.014 -.050 .043 .127
** -.033 1 
**Correlation is significant at the 0.01 level (2-tailed).     *Correlation is significant at the 0.05 level (2-tailed).
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Objective 3 
The third objective for this study was to determine which drugs community pharmacists 
believed would be acceptable additions to an expanded definition of nonprescription drugs 
under the FDA’s proposed “new paradigm”. A list of twenty five current “prescription-only” 
drugs was included in the survey and respondents were asked to determine whether a particular 
drug, assuming the establishment of an expanded nonprescription drug class under the FDA’s 
proposed new paradigm, should be dispensed as a prescription drug, new paradigm drug or sold 
over-the-counter. Definitions for the three response categories, “Dispensed as Prescription 
Only”, “Dispensed as a New Paradigm medication” and “Sold as Nonprescription Only” were 
provided to the respondents. Table 20 displays the results for objective 3. To summarize: 
The majority of respondents believed that the following drugs should be dispensed as 
prescription only: 
• Plavix® (clopidogrel bisulfate) 
• Ambien ® (zolpidem) 
• Medrol Dosepak ® (methyl prednisolone) 
• Imitrex ® (sumatriptan) 
The majority of respondents suggested that the following prescription-only drugs should be 
dispensed as “new paradigm” medications if established: 
• Lipitor® (atorvastatin) 
• Glucophage® (metformin) 
• HydroDIURIL® (hydrochlorothiazide) 
• Zestril® (lisinopril) 
• Viagra® (sildenafil) 
• Propecia® (finasteride) 
• Valtrex® oral (valacyclovir hydrochloride) 
• Benzaclin® (clindamycin benzoyl peroxide) 
• Zyban® (bupropion SR) 
• Vaniqa® (eflornithine) 
• Singulair® (montelukast sodium)  
• Proventil® inhaler (albuterol) 
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• Flonase® (flurticasone) 
• Tamiflu® (oseltamivir) 
• Diprolene® cream (betamethasone) 
• Zofran® (ondansetron)  
• Epipen® (epinephrine) 
• Phenergan® oral (promethazine) 
The majority of the respondents were of the opinion that the following prescription-only drugs 
should be sold as nonprescription or over-the-counter (i.e., without pharmacist intervention): 
• Prescription pre-natal vitamins  
• Clarinex® (desloratadine) 
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Table 20. Respondents’ Classification of Drugs into Dispensing Categories  
 
Drug Name 
Category under which the Drug should be Dispensed Total 
Dispensed as 
Prescription Only 
Dispensed as a 
“New Paradigm” 
Medication 
Sold as 
Nonprescription 
Only 
 
 N % N % N % N % 
Lipitor® 
(atorvastatin) 175 39.0 266 59.2 8 1.8 449 100 
Glucophage® 
(metformin) 201 44.8 242 53.9 6 1.3 449 100 
Plavix® (clopidogrel 
bisulfate) 383 85.3 63 14.0 3 0.7 449 100 
HydroDIURIL® 
(hydrochlorothiazide) 106 23.6 316 70.4 27 6.0 449 100 
Zestril® (lisinopril) 152 33.9 288 64.1 9 2.0 449 100 
Viagra® (sildenafil) 122 27.2 298 66.5 22 6.3 448 100 
Propecia® 
(finasteride) 154 34.4 259 57.8 35 7.8 448 100 
Valtrex® oral 
(valacyclovir 
hydrochloride) 
142 31.7 279 62.3 27 6.0 448 100 
Ambien® (zolpidem) 388 86.6 56 12.5 4 0.9 448 100 
Benzaclin® 
(clindamycin benzoyl 
peroxide) 
22 4.9 277 61.8 149 33.3 448 100 
Zyban® (bupropion 
SR) 210 47.0 221 49.4 16 3.6 447 100 
Prescription pre-natal 
vitamins 18 4.0 205 45.8 225 50.2 448 100 
Vaniqa® 
(eflornithine) 101 22.5 231 51.6 116 25.9 448 100 
Singulair® 
(montelukast 
sodium) 
159 35.7 248 55.6 39 8.7 446 100 
Proventil® inhaler 
(albuterol) 97 21.7 315 70.6 34 7.6 446 100 
Clarinex® 
(desloratadine) 9 2.0 149 33.4 288 64.6 446 100 
Flonase® 
(fluticasone) 42 9.4 298 66.8 106 23.8 446 100 
Tamiflu® 
(oseltamivir) 177 39.7 255 57.2 14 3.1 446 100 
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Diprolene® cream 
(betamethasone) 110 24.7 287 64.3 49 3.1 446 100 
Medrol Dosepak® 
(methyl 
prednisolone) 
243 54.5 199 44.6 4 0.9 446 100 
Zofran® 
(ondansetron) 149 33.4 271 60.8 26 5.8 446 100 
Imitrex® 
(sumatriptan) 278 62.3 160 35.9 8 1.8 446 100 
Epipen® 
(epinephrine) 117 26.2 288 64.6 41 9.2 446 100 
Phenergan® 
(promethazine) 124 27.8 276 61.9 46 10.3 446 100 
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DISCUSSION 
The FDA has been contemplating the implementation of a permanent third class of drugs 
in order to resolve some of the issues related to patient medication access. Initially, a “third 
class” or a “behind-the-counter” class of drugs was conceptualized as one under which 
medications could be dispensed without a physician’s prescription; however, pharmacist 
appropriation would be necessary.  Despite the fact that the idea of a third class of drugs has 
been debated since the 1960’s, FDA deliberations and hearings did not bring about the creation 
and establishment of such a drug class. Very recently, the third class debate was sparked again 
with a FDA hearing in March, 2012.  Unlike previous public hearings about expanding a BTC 
class of drugs, the 2012 public hearing entitled “Using Innovative Technologies and Other 
Conditions of Safe Use to Expand Which Drug Products Can Be Considered Nonprescription” 
repositioned a third class of drugs not as a BTC class, “but rather as a ‘new paradigm’ under 
which FDA “would approve certain drugs that would otherwise require a prescription for 
nonprescription use . . . under conditions of safe use” (Karst, 2012). Although in concept, the 
idea of expanding the current definition of nonprescription drugs, under the new paradigm, may 
appear to be similar to that of a third class of drugs but there are certain differences with respect 
to the drug specific conditions of safe use, and implementation of new technologies to help 
patients better self-assess their condition.  
Community pharmacists are the most important stakeholders for the implementation of 
the new paradigm and thus the FDA is seeking feedback on the new paradigm from community 
pharmacists at large. This study assessed attitudes of community pharmacists toward the new 
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paradigm with the help of a self-administered Internet survey. Community pharmacists’ attitudes 
were measured using a 7-point linear numeric scale with 1 = “Strongly Disagree” and 7 = 
“Strongly Agree”. Other specific objectives included evaluating differences in community 
pharmacists’ attitudes toward the new paradigm based on their demographic and practice 
characteristics and determining which drugs community pharmacists believe are be suitable 
additions to the new paradigm. 
Objective 1 
A principal components analysis (PCA) was conducted in order to identify the factors 
that comprise community pharmacists’ attitudes toward the new paradigm. Results from this 
analysis (Table 6) suggest that community pharmacists’ attitudes toward the new paradigm is 
comprised of six factors including patient care, workflow, patient safety, non-pharmacist 
providers, pharmacist burden and access.   
Respondents generally agreed with attitudinal statements regarding the “new paradigm” 
(per-item mean: 5.45 ± 0.86).  Respondents were generally positive about the provision of 
patient care under the proposed new paradigm and indicated there should be patient safety 
mechanisms in place.  Respondents felt significant workflow changes would have to be made to 
pharmacies, felt their own liability and workload would increase, and felt they should be 
reimbursed for services related to “new paradigm” drugs.  Respondents were largely ambivalent 
about the effect of the “new paradigm” on patients’ access to medications and how the workload 
of other health providers would be affected. Workflow change, liability and workload are issues 
the FDA will have to consider prior to the implementation of the new paradigm. Most 
importantly, the FDA must recognize that pharmacists desire to be adequately reimbursed for the 
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increased liability and workload associated with providing patient directed services under the 
new paradigm. 
  
Objective 2 
The second objective of this study was to assess differences in community pharmacists’ 
attitudes toward the new paradigm based on demographic and practice characteristics. The first 
variable explored was pharmacy type. Inherently, independent and chain pharmacies tend to be 
different with respect to their structure, workflow, prescriptions filled, and staff size. Results 
(Table 7 and 8) suggest that independent pharmacists more strongly agreed with statements 
regarding patient care then chain pharmacists. Pharmacists working in independent pharmacies 
were more likely to agree that pharmacists have the ability to provide patient care under the new 
paradigm and recognize the potential advantages of the new paradigm over the current system, 
specifically for the patient. Perhaps it is the structural differences described above that make 
independent pharmacists more sensitive to the patient care issues related to the “new paradigm”. 
Also, a search of the existing literature reveals that independent pharmacists have been known to 
provide better pharmaceutical care and/or Medication Therapy Management (MTM) for patients 
with chronic diseases such as asthma (Mclean and MacKeigan, 2005). Thus independent 
pharmacists may be more confident about providing patient care under the new paradigm. On the 
other hand, chain pharmacists were more likely to agree with workflow statements than 
independent pharmacists. This may suggest that chain pharmacists are more sensitive to the 
significant structural changes that would have to take place in the entire chain for which they 
work, not just their own store.  If and when the nonprescription drug class is expanded under the 
new paradigm, considerable structural changes will have to be made in the pharmacy to 
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incorporate extra space for drugs, patient counseling rooms and self-assessment kiosks for 
patients.  
The second demographic variable of interest was affiliation with a professional pharmacy 
organization (Table 9 and 10). Unlike pharmacists who are not associated with any professional 
organization, pharmacists who are affiliated to some professional pharmacy organization usually 
tend to be more progressive and ready for changes which would potentially further the value of 
the profession in providing patient directed care. Following the FDA’s March 2012 hearing, a 
large number of pharmacy organizations at the national, state and local level provided 
comments/suggestions with regard to the implementation of the new paradigm. Most 
professional pharmacy organizations such as the American Pharmacists Association, American 
Society of Health System Pharmacists, National Association of Boards of Pharmacy, and the 
National Community Pharmacists Association advocate for the implementation of an expanded 
nonprescription class of drugs. They believe that this would increase the involvement of the 
community pharmacy in patient treatment decisions and therefore further enhancing the value of 
the pharmacy profession. Respondents who were affiliated to at least one professional pharmacy 
organization more strongly agreed with patient care statements than pharmacists who were not 
affiliated with a professional pharmacy organization.  This finding is not surprising because 
pharmacists who are members of professional organizations are likely to be more progressive 
with respect to enhancing and achieving the goal of the profession to provide better patient care. 
They were also less likely to agree than respondents who were not members of a pharmacy 
organization that there would be significant workflow-related issues. This could be indicative of 
the fact that pharmacists affiliated with a professional pharmacy association are more progressive 
and accepting of shifts in current settings which would result in the improvement of the role of 
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the pharmacist in patient care. Thus they would be less sensitive to making changes in their 
current workflow settings for a step that would further the value of the profession. In fact, they 
may already be working toward achieving this goal.  
The third variable of interest was the location of the community pharmacy (i.e. rural or 
urban). One might expect that pharmacies in urban settings might be more progressive and thus 
more easily transition to changes like the “new paradigm.” However, no significant differences 
in attitudes toward the new paradigm were found between pharmacists who practiced in a rural 
versus ones who practiced in an urban setting (Table 11 and 12). The lack of significant 
differences may be indicative of the fact that there are many progressive pharmacies in rural 
areas as well.  
The fourth practice variable of interest was the region of the country where the 
respondent practiced (i.e. Northeast, Midwest, South and West). Respondents from the West 
more strongly agreed with patient care statements compared to those in the Northeast (Table 13 
and 14). To more clearly understand these findings, respondents’ comments and suggestions 
about the new paradigm were examined. One of the comments from a respondent practicing in 
Washington State suggested that about twenty five community pharmacists from Washington 
and California were in fact interested in implementing and experimenting with a system similar 
to the new paradigm as part of a collaborative practice model. Although limited in nature, this 
comment may, in part, suggest that respondents from the western regions of the country are more 
positive about implementing the “new paradigm” as compared to respondents from the 
Northeast. 
The fifth practice variable of interest was respondents’ positions in the community 
pharmacy (i.e., staff/relief/floater pharmacist, pharmacy manager/pharmacist-in-charge, 
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pharmacy owner). The responsibilities, liabilities, workload of a pharmacist in a community 
practice setting tend to vary based on his/her position in the pharmacy (Perepelkin et al., 2008). 
Considering this, it was expected that the views of community pharmacists toward the new 
paradigm would vary based on their role and position in their current pharmacy. The results from 
the analyses (Table 15 and 16) suggested that pharmacy owners and managers more strongly 
agreed with patient care statements then staff pharmacists. Staff pharmacists and pharmacy 
managers more strongly agreed with workflow statements than pharmacy owners. 
 Perhaps pharmacy owners and managers more strongly agreed with patient care 
statements because they have more practice experience, more advanced qualifications, or both. 
Also, perhaps inherently pharmacy owners and managers tend to be more entrepreneurial in 
nature than staff pharmacists. Therefore, it might be expected that pharmacy owners and 
managers would rate the patient care factor higher than staff pharmacists. 
 Another interesting finding in this study was that pharmacy owners were significantly 
less likely to agree with workflow statements compared to both pharmacy managers and staff 
pharmacists. When examining the workflow items, it appears that pharmacy owners did not think 
that workflow changes would be as significant or challenging as pharmacy managers and staff 
pharmacists did. While this finding appears counterintuitive, perhaps this is explained by the fact 
that owners are more adept at designing and making workflow changes.  Staff pharmacists may 
typically not be responsible for such workflow changes.  Pharmacy managers, assuming they are 
in the chain pharmacy setting would not typically be responsible for workflow changes either, as 
workflow changes in the chain setting are typically left to corporate decisions.   
Based on highest pharmacy degree earned (BPharm or PharmD), community 
pharmacists’ attitudes toward the new paradigm differed on patient care and non-pharmacist 
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provider statements. Respondents who had PharmDs as their highest degree more strongly 
agreed with patient care statements than respondents with a BPharm as their highest degree 
earned. This finding is not surprising because The PharmD curriculum across the United States 
generally tends to be more practice oriented as compared to the former BS in pharmacy program. 
The PharmD is a professional degree in pharmacy practice and individuals with this degree do 
tend to be more confident about practicing pharmacy, as compared to pharmacists with only a 
Bachelor’s in pharmacy, due to the 1-2 years of additional training that they have to undertake in 
school (Cox et al., 1988).  
Respondents with a PharmD also more strongly agreed with non-pharmacist provider 
statements than those with a BPharm as their highest degree. These statements reflected the idea 
that implementing the new paradigm would reduce burden and workload from other healthcare 
providers and services. PharmDs tend to be more oriented toward advancing the goal of the 
profession of providing better and more involved patient care than individuals who have a 
BPharm only and therefore they would generally be more receptive toward any initiative taken to 
that effect. Also, the nature of the PharmD curriculum tends to be more interdisciplinary in 
nature and thus PharmDs may be more familiar with the role of other healthcare professionals 
and therefore more acutely recognize the potential effect of the new paradigm on these other 
healthcare professionals as opposed to pharmacists with BPharm as their highest degree.  
In order to assess whether there were differences in community pharmacists’ attitudes 
toward the new paradigm based on number of years they actively practiced pharmacy, simple 
correlations were computed for the variable of interest (i.e. number of years of practice) with the 
various factors (or components) of respondent attitudes obtained from the PCA (Table 6). The 
number of years of actively practicing pharmacy was significantly and negatively correlated with 
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non-pharmacist providers and access. Specifically, pharmacists with greater number of years of 
experience were less positive about the belief that the new paradigm would reduce the workload 
on other healthcare providers and facilities. Also, later career pharmacists were less likely to buy 
into the role of the new paradigm in improving patient medication access. These findings align 
with the thought that pharmacists nearing the end of their professional career would have more 
negative attitudes toward the new paradigm as compared to pharmacists who are at the beginning 
of their career. Community pharmacists who are near the end of their career may not prefer any 
changes that would involve a major shift from the current practice system (such as the new 
paradigm) because such a transition might involve rigorous training and additional time 
commitments. While pharmacists who are at earlier stages of their professional career may be 
excited by thought of such a change because it would involve more involvement in patient 
treatment decisions and learning new skills overall which would help them at later stages of their 
career. Also, such pharmacists would have completed their education more recently and thus are 
more likely to have been trained in such paradigm shifts in the community practice model. 
However, the findings related to patient medication access related issues must be interpreted with 
caution because of low scale reliability (Cronbach’s alpha = 0.472) between the three items 
which loaded onto the factor. 
The last variable of interest was community pharmacists’ perceptions of their workload. 
Simple correlations were computed for this variable of interest with the various factors (or 
components) of respondent attitudes obtained from the PCA (Table 6). Respondent perceptions 
of their workload were significantly and positively correlated with workflow related issues 
surrounding the implementation of the new paradigm. This finding is intuitive because 
pharmacists who perceive that they already have a high workload would be more aware of the 
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significance in workflow related changes to their practice setting in order to implement the new 
paradigm. Respondents with greater perceived workload would be more sensitive to taking up 
any new responsibilities which would further increase their workload.     
Objective 3 
The third and final objective of this study was to assess what drugs community 
pharmacists believe would be potential additions to an expanded nonprescription drug class 
under the new paradigm if implemented. A list of twenty five current prescription-only drugs 
was created by referencing FDA guidelines on new paradigm drugs.  Respondents were asked to 
indicate whether a particular drug on the list should remain prescription-only, be dispensed as a 
“new paradigm” medication or whether it should be sold over-the-counter (Table 17).  
Respondents indicated that the majority of drugs on the list would be acceptable to dispense 
under the “new paradigm”. 
However, there were certain drugs on the list that respondents indicated should be 
dispensed as prescription-only drug even if the new paradigm was implemented. One such drug 
was Plavix® (clopidogrel).  Typically, Plavix® is indicated to prevent clotting of blood in the 
heart or any other blood vessels. However, side effects of Plavix® include internal bleeding such 
as in the stomach or intestines even if the patient has a minor injury. This drug is contraindicated 
for use with common drugs such as aspirin or other NSAIDs (Non-Steroidal Anti-Inflammatory 
Drugs). Thus it is in the best interest of the patient if Plavix® is prescribed after thorough 
examination by a physician rather than being dispensed as a new paradigm drug by the 
pharmacist.   
Another drug which community pharmacists believed should remain prescription-only 
was Ambien® (zolpidem). Ambien® is a sedative and is used to treat insomnia. It is habit-
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forming schedule IV controlled substance and therefore has a potential for abuse. Additionally, 
the use of this drug may lead to severe allergic reactions in certain patients. Therefore 
community pharmacists indicated that Ambien® should remain prescription-only in the best 
interest of the patients. 
On the other hand, there were two prescription-only drugs (Clarinex® (desloratadine) and 
prescription pre-natal vitamins) on the list that community pharmacists suggested should be 
switched to over-the-counter (OTC) status. This indicates that respondents believed that there is 
little or no need to monitor the usage of these drugs in the form of a prescription or pharmacist 
appropriation under the new paradigm. Clarinex® is indicated for allergic rhinitis and it does not 
have a severe adverse events profile unlike some of the above mentioned drugs. Additionally, 
other allergy medications such as Zyrtec® (cetirizine) (which were formerly prescription-only) 
are now available OTC. Therefore it is not surprising that respondents advocated the OTC sale of 
the drug. 
Limitations 
A national community pharmacist panel was used to collect data for this study and no 
monetary honorarium was provided to the respondents (although an executive summary of the 
findings was provided to the participants). Despite our recruitment letter statement that this study 
was being conducted for academic purposes, there is a strong potential of self-selection bias in 
this study. It is very likely that only respondents who were interested in the concept of the new 
paradigm (and in the final study results) may have participated in the study. However, because 
this study did not employ a factorial design, unequal group sizes did not appear problematic. 
A further analysis using the time trends extrapolation technique whereby the responses of 
first 10% and last 10% of the respondents are compared was conducted in order to test for the 
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presence of non-response bias (Tables 4 and 5). This technique is based on the assumption that 
late responders are very similar to individuals who did not respond at all. The results from this 
analysis suggested the presence of some non-response bias because early and late responders 
significantly differed in terms of age and number of years of practice. Late responders tended to 
be older (49.52 ± 1.68 versus 44.47 ± 1.65) and have a greater number of years of practice 
experience (23.82 ± 1.73 versus 18.04 ± 1.52) as compared to early responders. 
Generalizability of this study to all pharmacists across the United States may be 
questionable because this study employed a national convenience sample of community 
pharmacists.  However, the sample was stratified by region of the country where the respondents 
practiced in order to ensure that the distribution of the respondents was representative of the 
distribution of community pharmacists nationally based on the region of practice (i.e. northeast, 
south, mid-west and west). This study employed a cross sectional design and therefore causal 
relationships among the variables cannot be drawn. Future studies should employ alternative 
designs such as longitudinal data collection to more fully understand causal relationships among 
variables. 
Lastly, future researchers should consider the low scale reliability (α = 0.472) obtained for the 
sixth factor identified from the PCA of using these items for future studies. 
Directions for future research 
This study was preliminary in nature. It would be interesting for future researchers to 
assess whether or not the attitudes of community pharmacists, toward the new paradigm, 
measured in this study translate into willingness to adopt the new paradigm if it was 
implemented by the FDA. Future researchers should also try to measure the predictors of 
community pharmacists’ attitudes toward an expanded nonprescription drug class under the new 
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paradigm. A detailed evaluation of these predictors would provide great insight in understanding 
why community pharmacists have a particular outlook toward a specific aspect of the new 
paradigm. Also, with the help of the results of such a study the FDA would be able to pinpoint 
the type of community pharmacists and/or pharmacies who might be early adopters of the new 
paradigm when it is implemented. 
Also, it is important to know the opinions and perceptions of other healthcare 
professionals (i.e. physicians, nurse practitioners etc.) about the new paradigm because, although 
community pharmacists may be the most important stakeholders for implementing the new 
paradigm, such a move by the FDA would affect all healthcare practitioners and patients alike. 
Such a study would be relevant in providing feedback to the agency and help in determining if 
and how the new paradigm should be implemented. 
Conclusions 
Respondents were generally positive about the provision of patient care under the 
proposed new paradigm and indicated there should be patient safety mechanisms in place.  
Respondents felt significant workflow changes would have to be made to pharmacies, felt their 
own liability and workload would increase, and felt they should be reimbursed for services 
related to “new paradigm” drugs.  Respondents were largely ambivalent about the effect of the 
“new paradigm” on patients’ access to medications and how the workload of other health 
providers would be affected.  Finally, respondents indicated, with some exceptions that most of 
the 25 drugs they were provided could be considered “new paradigm drugs”, suggesting that 
pharmacists do see opportunity for such a drug class. 
At the end of the survey, respondents were given the opportunity to provide their 
thoughts about the new paradigm. There comments appeared to mirror their quantitative 
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assessments.  Most of the respondents suggested that it was an interesting concept and that the 
implementation of such a system would definitely be fruitful in increasing the role of community 
pharmacists in providing patient care. However, time constraints seemed to be a detractor for 
most pharmacists and the general consensus suggested that if the new paradigm was 
implemented then pharmacists should be reimbursed for the additional time spent on dispensing 
these to patients. 
The results of this study have several implications for the pharmaceutical industry, health 
care providers, and patients.  Such a drug class can impact strategies that pharmaceutical 
companies adopt for drugs nearing patent expiration.  Specifically, drug life-cycle extension 
avenues may be available to pharmaceutical manufacturers if a drug nearing the end of its patent 
term was approved for dispensing as a “non-paradigm” drug. Additionally the FDA may 
consider dual availability of a drug as both prescription and nonprescription under the “new 
paradigm”, a policy that could be potentially beneficial for manufacturers. However, changes to 
labeling, packaging, marketing, and promotion (especially direct-to-consumer advertising) 
requirements for “new paradigm” drugs would have to be considered.   
The “new paradigm” may affect the pricing and reimbursement of drugs entering this 
class. Additionally, pharmacist adoption of this third class may largely depend on reimbursement 
issues when considering the time required for them to appropriately dispense “new paradigm 
drugs” and investment required to potentially modify pharmacy workflow.  However, it could be 
argued that the role of the pharmacist in providing patient-directed care would increase, while at 
the same time reducing physician workload.   
Finally, for the patient, there is potential in increased medication access. However, 
patient safety may also be a concern if a new third class of drugs is not properly implemented.  
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While it is still unclear as to whether the “new paradigm” will come to fruition as proposed, it is 
important that stakeholder perspectives be considered by the FDA as they embark on this debate. 
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A) Characteristics of the Socio-Political context 
1. The new paradigm would increase the problem of "pharmacy shopping" among patients. 
2. Patients would have increased access to medications under the new paradigm. 
3. Patient medication adherence would improve under the new paradigm. 
4. For a given drug, the new paradigm would increase the out-of-pocket drug expenditures 
for insured patients. 
5. With the implementation of the new paradigm, patients would seek medical help more 
quickly than they do now. 
6. Patients would be accepting of pharmacists monitoring their treatment. 
7. Patients would be able to gauge their own health status using kiosks and online 
questionnaires. 
 
B) Characteristics of the Innovation 
1. The new paradigm would allow for more pharmacist-directed patient care. 
2. The new paradigm would foster better physician-pharmacist relationships. 
3. The new paradigm would reduce physician workload. 
4. The new paradigm would alleviate primary care physician shortages. 
5. The new paradigm would foster better patient-pharmacist relationships. 
6. The new paradigm would reduce the burden on emergency rooms. 
7. The new paradigm would increase the professional liability of a pharmacist. 
8. The new paradigm would increase pharmacists' workload. 
C) Characteristics of the Pharmacy 
1. Pharmacies would be willing to make significant structural changes to incorporate extra 
space for patient counseling rooms for the new paradigm. 
2. Pharmacies would be willing to make significant structural changes to incorporate extra 
space for an expanded nonprescription drug section for the new paradigm. 
3. Pharmacies would have to increase the number of personnel if the new paradigm were 
instituted. 
4. Pharmacies would be willing to train pharmacists for the new paradigm.  
5. Pharmacies would be willing to install innovative technologies such as diagnostic tests, 
kiosks, and computer algorithms under the new paradigm. 
6. Adopting the new paradigm would require a significant change in workflow for 
pharmacies. 
7. Adopting the new paradigm, if instituted, should be mandatory for all pharmacies. 
8. The new paradigm could increase the profitability of a pharmacy. 
9. It would be difficult to implement the new paradigm in the current community pharmacy 
setting. 
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D) Characteristics of the Adopting Pharmacist 
 
1. Pharmacists would have time to assist patients in selecting the most appropriate 
nonprescription medication under the new paradigm. 
2. Pharmacist-authorized refills upon a physician’s initial prescription should be permitted 
under the new paradigm. 
3. When in doubt, pharmacists should refer patients to a physician before dispensing a 
nonprescription medication under the new paradigm.  
4. Pharmacists should alert the physician if there are problems with the nonprescription 
medications that the patient is taking under the new paradigm. 
5. Pharmacists should be reimbursed for the time they spend diagnosing and counseling a 
patient under the new paradigm. 
6. Patient counseling by pharmacists for new paradigm drugs should be mandatory. 
7. Under the new paradigm, pharmacists would be comfortable ordering diagnostic/lab tests 
before dispensing certain nonprescription drugs. 
8. Under the new paradigm, pharmacists should document the nonprescription medication 
history of a patient. 
9. Pharmacists have the skills to make appropriate treatment recommendations under the 
new paradigm. 
10. Pharmacists should have access to patient medical records to dispense nonprescription 
drugs under the new paradigm. 
11. Pharmacist intervention would still be needed if innovative technologies that help 
patients self-assess their drug choices are instituted under the new paradigm. 
12. I am a proponent of instituting the new paradigm in pharmacy practice. 
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Dear Pharmacist, 
A few months ago, the FDA held a public hearing to obtain input on a new paradigm it is 
considering. Under this new paradigm, the FDA would approve certain prescription drugs for 
nonprescription use, but only under certain conditions to assure safe use of the drug by patients. 
The FDA is eliciting public comment on this proposed new paradigm. Arguably community 
pharmacists are the most important stakeholders for implementing the new paradigm. As a part of 
my thesis requirements, I am conducting a survey to obtain input from community pharmacists 
and assess their views about the new paradigm. Your response is important as we want to make 
sure that we have an accurate estimate of pharmacists’ attitudes toward the new paradigm. The 
completion of the survey should not take more than fifteen minutes of your time. Please consider 
completing your survey today.   
The responses to this survey will be kept confidential. This study has been reviewed by The 
University of Mississippi’s Institutional Review Board (IRB). Our IRB has determined that this 
study fulfills the human research subject protections obligations required by state and federal law 
and University policies.  If you have any questions, concerns, or reports regarding your rights as a 
participant of research, please contact the IRB at 662-915-7482.  If you have any questions about 
this project, please contact Dr. Erin Holmes, faculty in the department of Pharmacy Administration 
at the University of Mississippi at 662-915-5914. 
Follow This Link to the Survey: 
Or Copy and Paste the following Link in your internet browser: 
 
Thanks you in advance for your thoughtful consideration of this request.  
 
Respectfully, 
Ruchit Shah 
Graduate Student 
The University of Mississippi 
Department of Pharmacy Administration 
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